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Abstract 
Cigarette smoking and dietary patterns are associated with colorectal cancer 
(CRC) incidence; however, little is known about their influence on survival after CRC 
diagnosis. This study was designed to: 1) investigate the association of dietary 
patterns with all-cause (overall survival; OS) and disease-free survival (DFS) among 
CRC patients; 2) examine the association of smoking with OS and DFS among CRC 
patients.  
A cohort of 750 CRC patients diagnosed from 1999 to 2003 in the Canadian 
province of Newfoundland and Labrador was followed for mortality and recurrence 
until April 2010. Participants reported their smoking history and dietary intakes using 
a personal history questionnaire and a food frequency questionnaire. Dietary patterns 
were identified with factor analysis. Multivariate hazard ratios (HRs) and 95% 
confidence intervals (CIs) were calculated with Cox proportional hazards regression, 
controlling for major known prognostic factors.  
Results from this study are presented in two parts: 1) Disease-free survival among 
CRC patients was significantly worsened among patients with a high dietary intake of 
processed meat (the highest versus the lowest quartile HR: 1.82, 95%CI: 1.07-3.09). 
No associations were observed with the prudent vegetable or the high sugar patterns 
and DFS. The association between the processed meat pattern and survival in CRC 
patients was restricted to patients diagnosed with colon cancer (the highest versus the 
lowest quartile: DFS: HR: 2.29, 95%CI: 1.19-4.40; OS: HR: 2.13, 95%CI: 1.03-4.43). 
Potential effect modification was noted for sex (DFS: P=0.04, HR: 3.85 for women 
and 1.22 for men). 2) Compared with never smoking, current (HR: 1.78; 95%CI: 
1.04-3.06), but not former (HR: 1.06; 95%CI: 0.71-1.59), smoking was associated 
with decreased OS, although this association was limited to tumors in the colon. The 
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associations of cigarette smoking with the study outcomes were higher among patients 
with >40 pack-years of smoking (OS: HR: 1.72; 95%CI: 1.03-2.85; DFS: HR: 1.99; 
95%CI: 1.25-3.19). Potential interaction was noted for sex (DFS: P=0.04, HR: 1.68 
for men and 1.01 for women) and age at diagnosis (OS: P=0.03, HR: 1.11 for patients 
aged < 60 and 1.69 for patients aged 60). 
In summary, 1) processed meat dietary pattern prior to diagnosis is associated 
with higher risk of tumor recurrence, metastasis, or death from any cause among 
colon cancer patients; 2) pre-diagnosis cigarette smoking is associated with worsened 
prognosis among patients with colon cancer.  
 
Key Words: Colorectal cancer, smoking, dietary pattern, cancer survival, interaction,   
MSI, BRAF V600E 
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Chapter 1  Introduction  
1.1 Background 
Colorectal cancer (CRC) is a major health problem in Canada, with an estimated 
22,200 new cases and 8,900 deaths in 2011 [1]. CRC incidence and mortality rates 
vary by geographic region. In particular, Newfoundland and Labrador (NL), 
according to Canadian Cancer Statistics, has the highest age-standardized incidence 
and mortality rates of CRC in Canada. It is estimated that in the province of NL alone 
530 people will be diagnosed with CRC and 240 will die from it in 2013 [2].  
It seems likely that the high rates of the disease in NL are due in part to the 
remarkable hereditary predisposition to CRC in this population (recent research has 
observed a very high prevalence of indicators of familial risk among CRC patients in 
NL [3]); however, environmental factors have been shown to be important causes of 
CRC as well [4-8], which have been supported by evidence from migrant studies. 
Such studies report that when people migrate from low-risk areas of CRC such as 
Japan or Polish to high-risk areas such as United States or Australia, they approach 
the risk profile of the host country gradually [4, 5, 7]. To date, epidemiological 
research has identified a variety of environmental and lifestyle factors that appear to 
be known or putative risk factors for CRC. These include smoking, alcohol 
consumption and physical activity levels; however, the results have often been 
conflicting. 
It is generally believed that diet would strongly influence CRC risk, and up to 70% 
of this cancer burden could be reduced by alterations in dietary habits [9]. 
Accumulating evidence has indicated that high consumptions of red meat products 
and low intakes of fibre and dietary calcium are associated with increased CRC risk 
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[10-12]; however, there has been minimal research examining the association between 
dietary factors and survival after CRC diagnosis [13, 14]. Furthermore, most existing 
nutrition studies have focused primarily on individual foods or nutrients. Since foods 
and nutrients act synergistically rather than in isolation [15-18], any assessment of 
single effect of individual food is likely to be confounded by other foods in the diet 
[19, 20]. In addition, individuals eat freely; the amount and type of single food they 
consumed may frequently change, but the dietary patterns are relatively entrenched. 
Thus, a growing body of research has utilized dietary patterns to investigate the role 
of diet in cancer carcinogenesis. Dietary patterns identified in prior research often 
include the ―Western‖ and ―prudent‖ patterns. Adherence to the Western diet pattern, 
characterized by high intakes of meat, fat, sweets and desserts, is often associated 
with increased risk of CRC [17, 18, 21-23]. Whereas strong adherence to the prudent 
pattern, characterized by high intakes of fruit, vegetable, fish and poultry, often shows 
an inverse [21, 22] or null [17, 18, 24] association with CRC risk. To our best 
knowledge, however, there is only one study that specifically investigated the 
relationship between dietary patterns and survival among CRC patients. That 
prospective cohort study of 1009 stage III colon cancer patients [23] reported a 
deleterious disease-free colon cancer prognosis for patients reporting high levels of 
the Western dietary intake. Conversely, the authors observed no significant association 
between the prudent dietary pattern and cancer recurrence or mortality. 
Newfoundland and Labrador (NL) is the most eastern province in Canada. 
Geographically isolated in the Atlantic Ocean, NL has long maintained a 
Western-style diet consisting of a large proportion of processed meat, red meat and 
insufficient amount of vegetables [12]. Several studies have partially attributed the 
high CRC incidence rate in NL to its unique diet [12, 25, 26], but no study has 
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explored the association between the NL diet and its impact on survival among CRC 
patients.  
Cigarette smoking is another modifiable lifestyle factor associated with CRC 
tumorigenesis. In 2011, cigarette smoking was estimated to account for more than 20% 
of all deaths in Canada and 6 million deaths worldwide [27]. Moreover, more than 16% 
of Canadians over the age of 15 still smoke [28]. Smoking is clearly associated with 
malignancies in lung and larynx as well as chronic respiratory diseases [29]. In its 
2012 monograph, the International Agency for Research on Cancer (IARC) listed the 
colorectum among the tumor sites for which there is sufficient evidence of 
carcinogenesis by tobacco smoking [30]. Carcinogens in cigarettes, such as polycyclic 
aromatic hydrocarbons (PAHs) and aromatic amines [31-33], may reach the bowel 
mucosa through direct ingestion [34] and through the circulatory system [35], thus 
inducing DNA damage in colorectum mucosa cells, thereby increasing CRC incidence. 
Recent data suggest that the association of smoking and CRC incidence may differ by 
tumor molecular phenotype, although this evidence base is still emerging [36, 37]. 
The influence of smoking on CRC survival is unclear. Some studies [37, 38] have 
suggested that cigarette-use is strongly associated with reduced survival among CRC 
patients, whereas other studies have reported no significant differences in survival 
rates between smokers and never smokers with CRC [39-41]. The apparent 
discrepancy between studies is attributed to the long induction period of CRC [29], as 
well as the potential for modulating effects of important prognostic variables [42-44], 
many of which were not accounted for in the previous studies. For example, the 
microsatellite instability-high (MSI-H) phenotype and the somatic p.V600E BRAF 
mutation are strongly associated with both smoking status [45] and cancer prognosis 
[43, 46, 47], thus a potential interaction between smoking and these tumor phenotypes 
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should be appreciated. To date, only one study has explored the potential interaction 
between smoking and molecular tumor phenotype on mortality among CRC patients; 
this study showed a prominent association between smoking and CRC-specific 
mortality among patients whose tumors exhibited the MSI-H phenotype [37].  
Together, the influence of dietary patterns and cigarette smoking on patients‘ 
survival after CRC diagnosis has been inadequately examined. Novel research is 
clearly needed to explore these associations, if any. 
 
1.2 Study Purpose and Hypotheses 
Using the data of more than 700 colorectal cancer patients in Newfoundland and 
Labrador, the study presented in this dissertation aims to: 
1) Investigate the associations of dietary patterns and colorectal cancer all-cause 
(overall survival; OS) and disease-free survival (DFS). 
2) Explore if the relationship between dietary pattern and colorectal cancer survival 
is modified by sex, physical activity levels and BRAF V600E mutation. 
3) Examine the association of smoking with colorectal cancer all-cause and 
disease-free survival. 
4) Assess potential interactions of smoking with sex, age at diagnosis, tumor stage at 
diagnosis, MSI status, and BRAF V600E mutation status on survival among 
colorectal cancer patients. 
We hypothesize that prediagnostic ―Western‖ dietary pattern and cigarette 
smoking are associated with poor survival among CRC patients. 
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1.3 Organization of the Thesis  
The thesis is organized as follows: 
Chapter 1 is an overall introduction to this study. Chapter 2 reviews the literature 
and briefly summarizes the epidemiology of CRC, molecular pathways of CRC, as 
well as relevant risk and prognostic factors associated with CRC. Chapter 3 and 
Chapter 4 are two distinct but related subprojects, each including its own Methods, 
Results, and Discussion section. Chapter 5 summaries the key findings, discusses the 
implications and limitation of the study, and finally makes suggestions for further 
research directions.  
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Chapter 2  Literature Review  
2.1 Overview 
Colorectal cancer (CRC) is the third most frequent cancer and the fourth leading 
cause of cancer death, with approximately 1,230,000 new cases and 608,000  
deaths worldwide per year [48]. The impact of CRC is huge, not only because of its 
adverse influence on individual‘s overall quality of life [49] but also because of the 
loss in life years caused by the disease, which is only exceeded by lung and breast 
cancer in North America (932,000 years in total in 2012) [50]. Therefore, there is a 
compelling need for novel research to explore potential modifiable factors 
associated with CRC risk and survival, so as to inform prioritization of control 
strategies to reduce cancer risk in susceptible populations and to maximize survival 
of cancer patients [51].   
 
2.2 Epidemiology of CRC 
2.2.1 CRC Incidence and Trends 
Colorectal cancer has a ten-fold variation in international incidence, with the 
highest rates being observed in Australia, New Zealand, and parts of Europe, 
followed by North America, and the lowest in Asia, Africa and most of Latin 
America, ranging from more than 60/100,000 to less than 5/100,000 people [48, 52]. 
Indeed, the developed regions account for almost 60% of all CRC incidence [48]. 
The geographic variation suggests environmental causes of CRC, which has also 
been supported by the fact that immigrants rapidly reach the incidence rates of the 
adopted country [5, 7]. In Canada, the 2010 age-standardized incidence rate of CRC 
was 62/100,000 among men and 41/100,000 among women, with the highest 
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incidence rate being observed in NL [53]. More than half of new CRC cases 
occurred among people aged 70 years or older [53]. Meanwhile, CRC incidence was 
found substantially higher in men than in women. 
More recently, Center and his colleagues in American Cancer Society led a new 
study [54] that comprehensively reviewed CRC incidence data from 51 cancer 
registries worldwide from the Cancer Incidence in Five Continents (CI5) databases. 
They analyzed the change in incidence rates over the past 20 years: 1983-1987 
through 1998-2002, and found that CRC incidence increased significantly, especially 
for males, for 27 out of 51 cancer registries included in the analysis. The greatest 
increases were seen in economically transitioning countries including most of Asia, 
and select countries of Eastern Europe and South America. In particular, in Miyagi, 
Japan, rates increased by 92% in men and 47% in women. The author ascribed the 
substantial increase in CRC in economically transitioning countries to the progressive 
―westernization‖ of lifestyles in these populations. Many changes in modifiable 
lifestyle habits due to ―westernization‖ are suspected to increase CRC risk, including 
high consumption of red/processed meats, physical inactivity, and increased 
prevalence of smoking behavior [54]. However, this increase in CRC incidence may 
also be attributable, at least partly, to improved reporting and diagnostic techniques in 
these countries. The only country where CRC incidence gradually decreased was the 
United States [54]. 
However, the long-term data cannot capture short-term fluctuation of rate change. 
According to the 2011 Canadian Cancer Statistics, the incidence of CRC in Canada 
increased substantially between 1982 and 1985, then declined through the mid-1990s, 
and rose slightly to 2000; thereafter, the incidence of CRC declined slightly [1]. A 
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major reason for recent declines in CRC incidence might be the high screening rates.  
 
2.2.2 CRC Mortality and Trends 
About 608,000 deaths from CRC are recorded worldwide in 2008, that is, nearly 
8% of all cancer deaths, making CRC the fourth most common cause of 
cancer-related death [48]. The highest CRC mortality rates in both sexes are seen in 
Central and Eastern Europe, while the lowest rates are observed in Middle Africa 
[48]. In recent years, the mortality rate of CRC has declined significantly in regions 
such as United States, New Zealand, Australia, and Western Europe [55-57], but 
increased at a crude rate of 5-15% per year in some parts of Eastern Europe [52]. 
In Canada, the age-standardized mortality rate was 25/100,000 among men and 
15/100,000 among women in 2011, with the highest mortality rate seen in NL, 
which is almost twice of that in British Columbia for males [1]. According to the 
2011 Canadian Cancer Statistics [1], over the past sixteen years, mortality due to 
CRC in Canada has been decreasing by approximately 1.5% every year in males and 
1.8% in females. This decline in mortality highlights the improvements made in 
screening, early detection, training program, and treatment for colorectal cancer, for 
example, including new chemotherapeutic agents [1]. 
 
2.2.3 CRC Survival and Prognosis  
Colorectal cancer survival is closely correlated with stage and histological grade 
of disease at diagnosis. Generally, the earlier the stage at diagnosis, the longer the 
time of survival. It has been estimated that the 5-year survival rate for CRC is over 90% 
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for patients with tumors detected at the localized stage; 70% for regional cancers, and 
only 10% for people diagnosed with distant metastatic CRC [58]. 
There is enormous variability in CRC survival worldwide. The geographical 
differences in survival is likely due to global/regional inequalities in prompt cancer 
detection and treatment of disease [52]. However, survival for CRC at all stages has 
been increasing substantially on a world scale over the past decades [52, 58]. Recent 
progress in cancer control and treatment are definitely one of the reasons that can 
explain such increasing trend in CRC survival.  
 
2.3 Molecular Pathways of Colorectal Carcinogenesis 
Genomic instability is a major driving force for the transformation of normal 
colorectal mucosa to carcinoma, and three distinct molecular pathways have been 
implicated in CRC development [59]; these are the chromosomal instability (CIN) 
pathway, the microsatellite instability (MSI) pathway, and the serrated pathway, which 
are largely distinct from each other but are not mutually exclusive [59].  
 
2.3.1 The Chromosomal Instability Pathway 
The majority (approximately 65%-70%) of sporadic CRCs arise through the 
chromosomal instability pathway, which is induced by defects in chromosome 
segregation, telomere dysfunction, or defects in the DNA damage response system 
[60]. The CIN pathway is characterized by aneuploidy, chromosomal genomic 
amplifications, and loss of heterozygosity [59]. Allele gains related to the CIN 
pathway are commonly found on chromosomes 7, 8q, 13q, 20 and X, while allele 
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losses are often detected on 1, 4, 5, 8p, 14q, 15q, 17p, 18, 20p, and 22q [60]. These 
insertions or deletions frequently cause mutations affecting some critical oncogenes 
and tumor suppressor genes, such as adenomatous phlyposis coli (APC) gene, K-ras, 
p53 and SMAD genes [61], and mutations in the APC and K-ras genes are 
the commonest genetic alternations [60]. 
The Wnt signaling pathway plays a principal role in both CRC initiation and 
progression [60]. This pathway is triggered by β-catenin through binding to T-cell 
factor (TCF)/lymphoid enhancer factor (LEF), which initiates the transcription of Wnt 
target genes [62]. Normally, the APC functions to modulate the Wnt signaling 
pathway through negative regulation of β-catenin. However, loss of APC gene 
function caused by specific mutations may lead to accumulation of cytosolic β-catenin, 
thereby resulting in nuclear translocation and over-activation of Wnt signaling 
pathway [60].  
K-ras mutation is observed in 30-60% of CRCs and most adenomas [63, 64]. The 
K-ras oncogene produces a 21 kDa membrane bound protein that functions to 
transduce cellular signals. The K-ras protein is normally hydrolyzed by GTPase. 
However, specific mutations can result in decreased intrinsic GTPase activity. Its 
inability to deactivate K-ras allows K-ras to maintain an activated form. The activated 
K-ras oncogene promotes the transition from adenoma to carcinoma by activating 
downstream targets such as BCL-2, H2AFZ, RAP1B, TBX19, and MMP1 [60, 63].  
 
2.3.2 The Mismatch Repair deficient, Microsatellite Instability Pathway 
Microsatellites are ―short tandem repeats‖ (STRs) in DNA sequences that spread 
over the whole genome [60]. Microsatellite DNA is intrinsically unstable and error 
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prone. The DNA mismatch repair (MMR) system normally recognizes and corrects 
mismatch errors that are generated during DNA replication [65]. Several genes 
function in MMR, such as MLH1, MSH2, MSH6 and PMS2. Inadequate MMR 
function would lead to frameshift mutations in the microsatellite repeats and therefore 
gene inactivation, known as instability of microsatellites [66]. It is estimated that 
about 15% of all CRCs evolve through the MSI pathway; of these, approximately 3% 
are correlated with Lynch syndrome due to the inherited mutations in MMR genes, 
and the remaining 12% are sporadic, caused by promoter hypermethylation of 
the MLH1 [67]. MSI tumors have a distinct profile, for example, including a tendency 
to occur in the proximal colon, to have lymphocytic infiltrate, and to be mucinous and 
poorly differentiated [67, 68]. Furthermore, microsatellite instability-high (MSI-H) 
tumors are often associated with better survival than microsatellite stable (MSS) 
tumors [65]. 
 
2.3.3 Serrated Pathways 
The serrated pathway, accounting for approximately 10%-20% of CRCs, is highly 
correlated with both the CpG island methylator phenotype (CIMP) and the BRAF  
V600E mutation [69].  
 
2.3.3.1 CpG Island Methylator Phenotype 
CpG Island Methylator Phenotype refers to the presence of concordant 
methylation in multiple tumorigenesis-related genes [60]. There are generally two 
types of CIMP in sporadic cancers: CIMP high and CIMP low. Weisenberger et al. [70] 
proposed a robust panel of markers to distinguish CIMP high from CIMP low status 
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including markers in CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 genes. DNA 
methylation of at least three out of these five markers is defined as CIMP positive, and 
approximately 15-20% of sporadic CRC exhibit CIMP-high [60]. Most sporadic MSI 
colon tumors are CIMP positive, but CIMP is rarely detected in MSI-H tumors arising 
from Lynch syndrome, suggestive of distinct underlying molecular mechanisms [70, 
71]. CIMP and the clinicopathologic features of CRC have been widely investigated. 
Specifically, CIMP is significantly more frequent in females, senior age groups, and 
tumors of the proximal colon [71-73]. Moreover, CIMP-high cancers are associated 
with poor tumor differentiation, microsatellite unstable tumor phenotype, BRAF 
V600E mutations, K-ras mutations, and wildtype p53 [72-75]. Finally, Ogino et al. 
[73] reported a significant relationship between CIMP-high and a low CRC-specific 
mortality that is independent of other molecular phenotypes.  
 
2.3.3.2 BRAF V600E Mutant Phenotype 
BRAF V600E is a somatic mutation observed in colorectal tumors. This mutation 
results in a substitution of a valine amino acid with a glutamic acid amino acid at 
position 600 in the BRAF protein [76]. The BRAF V600E mutation is found to be 
tightly correlated with the CIMP and the MSI pathways [70, 74], whereas it is 
uncommon in Lynch syndrome-related cancers that exhibit MSI-H [77]. BRAF V600E 
mutant CRC accounts for 10-18% of all CRCs and normally has distinct features. It is 
more common in females, smokers, and proximal colon location (right colon) [78-80]. 
Pathologically, tumors harboring the BRAF V600E mutation are often poorly 
differentiated, and hence they are associated with a poor prognosis [81]. 
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2.4 Factors Associated with CRC Incidence 
The causative etiology of CRC is complex and multi-factorial [82].  
Approximately 15% to 20% of all CRCs are familial, and several heritable risk factors 
and CRC susceptibility genes are implicated [83]. On the other hand, the majority of 
CRC cases are sporadic; they arise through cumulative effects of environmental 
factors and the complex interaction between heritable genetic and environmental 
components [84].  
 
2.4.1 Family History  
Family history is one of the most consistent risk factors for CRC. People with a 
positive family history of CRC have a two- to four-fold increased risk of developing 
CRC than those without it [85]. The risk is higher among people whose relatives have 
early-onset CRC (age at diagnosis <50) than those whose relatives are diagnosed later 
[86]. Hence, the joint guideline for early detection of CRC developed by multiple 
organizations—the American Cancer Society, the US Multi Society Task Force on 
CRC, and the American College of Radiology—recommends early screening for 
individuals who have a family history of CRC [87]. 
Part of the familial risk can be attributed to several inherited cancer syndromes, 
and two major CRC predisposition syndromes are familial adenomatous polyposis 
(FAP, 1% of all CRC cases) and hereditary non-polyposis colorectal cancer (HNPCC, 
5-7% of all CRC cases) [88]. Both are inherited in an autosomal dominant fashion. 
FAP is caused by inactivating mutation of a tumor suppressor gene, the adenomatous 
polyposis coli (APC) gene. Patients affected by FAP usually present with hundreds of 
adenomatous polyps in the colon, which will inevitability transform to carcinoma if 
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left untreated [89]; HNPCC results from mutations in mismatch repair genes, 
commonly MLH1, MSH2 and MSH6 [89]. More than 90% of tumors arising in 
HNPCC patients shows microsatellite instability [89]. 
In recent genome wide association (GWA) studies, there have been links 
identified between at least ten common low-penetrance variations and the occurrence 
of CRC [84]. Tenesa et al. [84] analyzed Scottish GWA data and reported that up to 
170 common independent variants were contributing to inherited susceptibility to 
CRC. To date, CRC susceptibility has been shown to be related to a variety of genes 
linked to chromosome segments 8q23.3, 8q24, 10p14, 11q23, 15q13, and 18q21 et al. 
[69, 90-93]. 
 
2.4.2 Modifiable Environmental Factors  
A wide range of environmental factors has been studied both experimentally and 
epidemiologically as potential risk factors for CRC; these include dietary factors, 
physical activity levels, and smoking. Each of these potential risk factors will be 
described individually in more detail. 
 
2.4.2.1 Diet Factors 
It is generally believed that diet would strongly influence the CRC risk through 
either physical interaction with the intestinal mucosa [69] or alterations in intestinal 
microbiota, which are strongly associated with colonic polyp formation and with the 
risk of developing CRC [94]. According to statistics, up to 70% of this cancer burden 
could be reduced by alterations in dietary habits [9]. 
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2.4.2.1.1 Total Energy and Macronutrients 
Although the 2007 WCRF/AICR expert report indicated that there is no simple 
association between total energy and CRC risk [95, 96], much evidence in the 
literature would suggest that intakes of total energy are positively associated with risk 
of CRC [97-99]. The underlying biological mechanisms are not fully understood, but 
it is suggested that high energy intake could induce glycemic overload and 
compensatory increase of serum insulin and insulin-like growth factor-1 (IGF-1), 
which may subsequently promote cell proliferation, inhibit apoptosis, and eventually 
elevate the risk of colorectal tumorigenesis [100-103]. 
Furthermore, evidence on relationships between CRC risk and intakes of 
macronutrients (e.g., carbohydrates, proteins, and fats) remains limited and sometimes 
inconsistent. For example, a 1990 report from the Nurses‘ Health Study linked the 
consumption of animal fat to an increased risk of CRC after the adjustment of total 
energy intake, but the authors found no correlation between vegetable fat and cancer 
initiation [104]. Conversely, several studies observed no effect of animal fat on CRC 
risk [105, 106]. Simultaneously, non-red meat sources of animal protein have been 
typically correlated with a reduced risk [100, 105], whereas total carbohydrate 
consumption has been linked with increased risk in some studies [107], but not others 
[95, 108]. 
 
2.4.2.1.2 Fruit, Vegetables and Fibre 
The majority of over 20 case-control (reviewed in [109]) and 7 cohort studies 
(reviewed in [110]) have suggested that high consumption of fruits and vegetables 
may be associated with a reduction of CRC risk. However, which fruits or vegetables 
account most for this reduction remains elusive. In the 9.6-year follow up of the 
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Swedish Mammography Screening Cohort Study [110], a protective effect was found 
for total fruit and vegetable consumption. However, little relation was seen between 
CRC risk and the intake of cereal fibre in this study. 
A meta-analysis of 13 case-control studies [111] suggested that dietary fibre may 
protect against CRC, although results from prospective cohort studies [112-114] have 
been essentially negative. Admittedly speculative, one possibility is that the protective 
effect of dietary fibre needs a much longer response latency than the follow-up time 
frame of the research that has failed to support such association [115]. 
 
2.4.2.1.3 Red and Processed Meat  
―Red meat‖ is generally defined as flesh from domesticated mammals, which is 
mainly comprised of red muscle fibres, such as beef, pork, lamb and goat; ―processed 
meat‖ refers to meats preserved by smoking, curing, or salting, to which 
nitrites/nitrates or other preservatives are artificially added, such as ham, bacon, and 
salami [116].  
To date, the evidence that links red and processed meat consumption to increased 
CRC risk is quite convincing—specifically, all of the 16 cohort studies and most of 
the 71 case-control studies that examine red meat and CRC risk (reviewed by the 
2007 WCRF/AICR expert panel [116]) have reported an increased risk for individuals 
in the highest intake group relative to those in the lowest, and an apparent 
dose-response effect has been observed. These observations are further supported by a 
recent meta-analysis of 15 prospective studies, which indicated that a daily augment 
in red meat consumption of 120 gram is associated with a 28% (95%CI: 18%-39% ) 
increase in CRC risk [117]. As well, twelve out of fourteen cohort studies (reviewed 
in [116]) have shown a positive association between processed meat intake and CRC 
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risk, with the association being statistically significant in four [104, 106, 118, 119]. A 
meta-analysis of five studies conducted by the panel gave a summary RR (relative risk) 
of 1.21 (95% CI 1.04-1.42) per 50 g/day augment of processed meat intake [116]. 
There are several mechanisms that may rationalize the associations observed 
between red/processed meat and CRC. First, fried or high-temperature cooked meat 
may contain carcinogenic heterocyclic amines and polycyclic aromatic hydrocarbons 
[116]. Many processed meats are also high in salt, nitrite, and nitrate that may 
promote the subsequent formation of endogenous N-nitroso compounds; these 
compounds are suspected human carcinogens and have been suggested as significant 
contributors for CRC development [120, 121]. Moreover, high consumption of red 
meat has been associated with increased iron level, which may catalytically stimulate 
the production of reactive oxygen species, and hence result in DNA damage [122, 
123]. 
 
2.4.2.1.4 Minerals and Vitamins 
Several antioxidants, for example, beta carotene, riboflavin, folate, and vitamins 
A, C and D have long been regarded as natural inhibitors that influence cancer 
initiation or progression [26, 124-127]. Since these antioxidants can provide 
antioxidant and anti-inflammatory effects, they are suggested to protect against CRC. 
In addition, dietary calcium and selenium have been consistently associated with a 
lower risk of CRC, whereas dietary iron has increased the risk because of its catalytic 
activity on the production of oxygen radicals [26, 128]. 
 
2.4.2.1.5 Dietary Patterns 
Most nutrition studies have focused primarily on individual food or nutrients. 
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Since food and nutrients act synergistically rather than in isolation [15-18], recent 
research has investigated the role of dietary patterns on CRC incidence. Dietary 
patterns identified in prior research often include the ―Western‖ and ―prudent‖ 
patterns. Adherence to the Western diet pattern, characterized by high intakes of meat, 
fat, sweets and desserts, is often associated with increased risk of CRC [17, 18, 21-23]. 
Whereas strong adherence to the prudent pattern, characterized by high intakes of fruit, 
vegetable, fish and poultry, often shows an inverse [21, 22] or null [17, 18, 24] 
association with CRC risk. A recent review of data from existing cohort studies 
(2000-2011) [129] concluded that risk factors for CRC include Western diet, 
processed pork meat, traditional meat eating, potatoes, and refined grain pattern, while 
protective dietary patterns for CRC include healthy and prudent diet.  
It is not possible that the relationship between dietary patterns and CRC risk is 
attributable to a causal effect of any specific food, because each pattern contains a 
complex mixture of diverse foods, all of which may contribute to an effect [116]. 
Instead, it seems more likely that individual food and nutrient interact with each other 
and work together to give rise to CRC. Unfortunately, the existing investigations on 
dietary patterns and diseases are limited in number, and definitions for specific dietary 
patterns are rather different across studies.  
 
2.4.2.2 Cigarette Smoking  
Smoking has been widely investigated as a risk factor for incident CRC [130-139]. 
Most studies have reported that chronic smoking is associated with an increased risk 
of CRC incidence [130-137]. CRC risk also increases with an increasing number of 
pack-years and cigarettes per day in a dose-dependent manner [130, 131, 133, 134]. 
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Furthermore, the smoking-CRC association has been observed to be stronger for 
women than for men [136, 137] and for rectal cancer [140, 141]/proximal colon 
cancer [29, 142] than for the distal colon cancer. A comprehensive meta-analysis 
conducted by Botteri et al. [29] suggested that ever smoking was associated with an 
almost 20% increase in CRC risk compared with never smoking (RR: 1.18; 95%CI: 
1.11-1.25), while the risk estimates were higher for cancer of the rectum than of the 
colon in current smokers (P=0.02). Tsoi et al.
 
[140] examined a total of 1,463,796 
participants in 28 prospective cohort studies and concluded that current smokers 
carried a modestly higher risk of CRC relative to never smokers (RR: 1.20; 95%CI: 
1.10-1.30), and the increased risk of CRC was dose-related to higher levels of daily 
cigarette consumption/pack-years, and longer years of smoking. When stratified by 
tumor molecular subtypes, however, smoking appeared to be most strongly correlated 
with the risk of CRC that exhibited MSI-high [138, 139]. Among studies that assessed 
the effect of smoking cessation on CRC risk, three [137, 142, 143] reported no 
consistent trend in risk whereas two [136, 144] reported significantly increased risk 
with prolonged cessation time.  
 Nevertheless, some investigators have reported inconsistent results. Nyren et al. 
[145] examined a cohort of 135,000 Swedish construction workers and found no 
significant association between current smoking status, number of daily cigarette 
consumption or number of years smoking, and the risk of CRC. Even among heavy 
smokers with a long smoking duration (≥30 years at the beginning of follow-up), the 
age-adjusted RRs were not statistically significant. The reasons for the discrepancies 
in comparison with recent data might be that Swedish men have a tradition of snuff 
suction, which might have led to contamination of negative control, resulting in the 
hazardous effects of smoking not yet being detected. Another hospital-based 
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case-control study on CRC from India [146] also reported non-significant association 
between ever smoking and CRC (smokers vs. non-smokers: OR: 0.7; 95%CI: 0.4-1.1). 
For that analysis, smoking history was classified into categories of ever and never 
smoking; regrettably, effects of gradients of smoking duration or intensity on CRC 
were not examined. 
There are several biologic mechanisms that may explain the higher risk of CRC 
among smokers. First, carcinogens in cigarettes, such as polycyclic aromatic 
hydrocarbons and aromatic amines [31-33], may reach the bowel mucosa through 
direct ingestion [34] or through the circulatory system [35], thus exerting growth 
promoting effects on cancer cells in the colorectum and increasing CRC incidence. 
Second, tobacco smoking may mutate the GSTM1 gene, resulting in further impaired 
detoxification of these carcinogens [147]. Moreover, smoking may also induce 
aberrant promoter DNA methylation, thus silencing regulatory genes (e.g., ECAD, p16, 
MGMT, and DAPK) in tumor initiation and promotion [148]. 
 
2.4.2.3 Physical Activity Levels 
Physical inactivity is a well-accepted risk factor for CRC that is independent of 
other confounders including obesity [69]. Physical activity is suggested to improve 
body‘s metabolic efficiency and to reduce blood pressure and insulin resistance. 
Nearly all of the existing cohort and case-control studies investigating physical 
activity and CRC demonstrated a decreased risk of developing the disease with 
increased habitual levels of physical activity, except for one early study that reported a 
positive but non-significant association between physical activity and CRC among 
men who aged <45 years (RR: 2.23; 95%CI: 0.88-5.66) [149]. It is estimated that high 
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habitual levels of physical activity could reduce up to 50% of all incident CRC [150], 
and engaging in two hours or more of physical activity per week could significantly 
reduce CRC risk in most people [151]. 
 
2.5 Factors Associated with CRC Survival 
2.5.1 Clinicopathologic Factors 
Most known factors that influence CRC survival are clinicopathologic features 
which are regrettably unmodifiable, including tumor stage, histological grade, 
treatments received, and tumor molecular phenotype. 
In particular, the tumor stage and histological grade of CRC have been well 
documented in the literature as indicators of severity of disease and chance of survival. 
The 5-year survival rate was estimated at over 90% for tumors detected at the 
localized stage; 70% for regional, and only 10% for people diagnosed for distant 
metastatic CRC [58]. For those metastatic CRCs, receiving an accepted form of 
systemic treatment appears to largely lengthen the median survival time of CRC 
patients (from less than 9 months without any treatment to about 24 month in Wolpin 
et al.‘s [152]). 
Furthermore, there is some evidence that associations exist between selected 
tumor molecular features and survival from CRC. For instance, MSI-H CRCs has 
been linked to an excellent 5-year survival, while BRAF-mutant tumors have 
portended a poor survival [46, 47, 153].  
Besides, FLT2 and KDR are primary receptors for the vascular endothelial 
growth factor-A (VEGFA); they may influence tumor progression via promoting 
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angiogenesis [154]. Slattery et al. [154] analyzed data from a case-control study of 
more than 5,000 participants and found that four single-nucleotide polymorphisms 
(SNPs) in FLT1 were predictive of colon cancer survival while three SNPs in KDR 
were predictive of rectal cancer survival. 
 
2.5.2 Modifiable Environmental Factors 
2.5.2.1 Diet Factors 
2.5.2.1.1 Total Energy and Macronutrients 
Epidemiological evidence on the association between intake of total energy and 
CRC survival remains controversial. Dray et al. [14] analyzed 10-year survival data 
on 148 patients who received resection of the tumor and concluded that high energy 
intake, resulting from high intakes of carbohydrate, protein, and lipid, was strongly 
correlated with better 5-year survival, the HR for the highest tertile of energy intake 
being 0.18 (95%CI: 0.07-0.44) in comparison to the two lowest tertiles. Likewise, 
Slattery et al. [13] examined the influence of diet in 411 colon cancer cases in Utah. 
After the adjustment of major known prognostic factors, the highest quartile of intake 
for total calories, fat and protein was associated with increased cancer survival, HRs 
being 0.60, 0.80, and 0.66 respectively. Nevertheless, some recent data somewhat 
contradicted the intriguing results from Dray‘s and Slattery‘s. For example, one study 
[155] showed an adverse impact of a diet high in carbohydrates on disease-free 
survival, recurrence-free survival, and overall survival for colon cancer patients. 
Sichieri et al. [156] found that total fat intake was possitively associated with CRC 
mortality. The contradictory results are likely due in part to adverse causal or residual 
confounding by other factors such as disease stage at diagnosis that had not been 
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adjusted for in earlier studies.  
 
2.5.2.1.2 Fruit, Vegetables and Fibre 
Ever since Burkitt [157] proposed the hypothesis that the lower CRC mortality in 
blacks than that in whites was attributable to high dietary fibre consumption, the 
protective effects of fruit, vegetables and fibre against cancer mortality have aroused 
strong research interest. Diets higher in fruit and vegetables tend to be associated with 
a lower risk of CRC mortality [158]. The favorable roles of fruit and vegetables on 
CRC progression may be attributable not only to the antioxidant vitamins but also to 
their fibre content. This is supported by the findings from an ecological analysis of the 
Seven Countries Study [159] showing a strong inverse association between dietary 
fibre and CRC mortality. Intriguingly however, the Cancer Prevention Study II 
conducted by researchers from American Cancer Society observed some inverse 
associations between certain fruits rich in fibre and the risk of fatal CRC [160, 161]. 
Nor in the study by Dray et al. [14], a significant association has been observed 
between fruit, vegetables, and CRC survival.  
 
2.5.2.1.3 Red and Processed Meat  
Although red and processed meat has been confirmed as a moderate risk factor 
for CRC [162], minimal research has specifically examined its role in survival after 
CRC diagnosis. In the CRC gene-environment study supported by the National 
Cancer Institute [163], Zell et al. compared the overall survival rates for 511 CRC 
patients by quartile levels of prediagnostic meat consumption and found them to be 
significantly different among familial CRC patients (10-year OS: the highest quartile: 
42%, the lowest quartile: 65%; P=0.017), but not different among sporadic CRC 
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patients, indicating potential gene-environmental interactions. Likewise, McCullough 
et al. [164] examined 2,315 patients with CRC who reported both pre- and 
post-diagnosis diets in the Cancer Prevention Study II Nutrition Cohort. Results 
showed that neither pre- nor post-diagnosis red/processed meat consumption was 
significantly associated with CRC mortality risk. However, individuals with 
consistently high intakes of red/processed meat before and after diagnosis were 1.79 
(95%CI: 1.11-2.89) times more likely to die from CRC than those with consistently 
low intakes. In line with Zell et al.‘s [163], a borderline interaction between family 
history and red/processed meat was detected in McCullough‘s study, with a higher 
risk of all-cause mortality observed among patients who have a positive family history 
(P for interaction=0.05). The authors ascribed the observed interaction to genetic 
polymorphisms in the detoxification of carcinogenic mutagens (e.g., Heterocyclic 
Amines and Polycyclic Aromatic Hydrocarbons) that were often found in smoked, 
fried or high-temperature cooked meat [164]. 
 
2.5.2.1.4 Minerals and Vitamins 
Significant associations have been identified between selected minerals/vitamins 
and survival from CRC, for example, including protective effects of high premorbid 
levels of selenium, vitamin B6, retinol, β–carotene, lycopene, total carotene, and 
provitamin A [124, 165-167]. However, no consistent trend in risk for death as a result 
of CRC has been observed for any of the aforementioned nutrients in an ecological 
survey in 49 Chinese rural counties [158] nor in a study of 16 cohorts of the Seven 
Countries Study [168]. 
 
2.5.2.1.5 Dietary Patterns 
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Research that has examined the relationship between dietary patterns and 
survival among CRC patients are limited in number. The only study identified by our 
literature review investigated a cohort of 1,009 stage III colon cancer patients across 
North America from a randomized adjuvant chemotherapy trial [23]. In that study, 
two major dietary patterns—prudent and Western—were identified by factor analysis. 
The authors reported a significant detriment in colon cancer survival—defined as 
disease-free survival (HR: 3.25; 95%CI: 2.04-5.19; P for trend <0.001), 
recurrence-free survival (HR: 2.85; 95%CI: 1.75-4.63) and overall survival (HR: 2.32; 
95%CI: 1.36-3.96) —for patients in the highest quintile of Western dietary pattern 
intake, compared to those in the lowest quintile group. However, a prudent diet was 
not associated with either CRC recurrence or mortality. 
 
2.5.2.2 Cigarette Smoking 
Numerous studies have investigated the role of smoking in CRC survival with 
conflicting results. Most studies [37, 38, 169-171], but not all [39-41], have indicated 
that cigarette smoking is associated with greater risk of CRC mortality and worse 
survival, specifically for tumors located in the rectum than in the colon; however, the 
associations vary in both direction and magnitude. There have been four main studies 
that assessed the effect of smoking cessation on the risk of CRC mortality, two of 
which have reported protective effects of smoking cessation on CRC mortality risk 
[170, 171]. The other two [41, 172] have found no significant association. 
Based upon this, Botteri et al. [29] undertook a complete review of 106 
observational studies on cigarette smoking in relation to both CRC incidence and 
mortality. They reported that ever smoking relative to never smoking status was 
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linked with a 1.25-fold increased risk (95%CI: 1.14-1.37) [29]. The dose-response 
analyses suggested that the risk of CRC mortality increased linearly with increasing 
number of cigarettes smoked per day and prolonged duration of smoking. Specifically, 
an increase of 10 cigarettes/day (0.5 pack/day) and 10 years of smoking led to a 7.4% 
(95%CI: 5.7%-9.2%) and a 9.5% (95%CI: 5.5%-13.7%) increase in RRs for CRC 
mortality, respectively. Liang et al. [141] also examined 36 prospective studies and 
observed an approximately 40% (95%CI: 1.06-1.84) augment in RR for CRC 
mortality in current smokers compared to never smokers. For every additional 20 
cigarettes per day, the risk of CRC mortality increased by 40.7%.  
Nevertheless, other studies have reported no significant differences in survival 
rates between smokers and never smokers with CRC [39-41]. The apparent 
discrepancy between studies is attributed to the long induction period of CRC [29], as 
well as the potential for modulating effects of important prognostic variables [42-44], 
many of which have not been accounted for in the previous studies. To date, only one 
study has explored the potential interaction between smoking and molecular tumor 
phenotype on mortality among CRC patients; this study showed a prominent 
association between smoking and CRC-specific mortality among patients whose 
tumors exhibited the MSI-H phenotype [37].  
 
2.5.2.3 Physical Activity Levels 
Higher levels of physical activity have been associated with a lower risk of CRC 
mortality in previous epidemiological studies [173-175]. For example, in a study of 
CRC survival, Campbell et al. [175] examined 184,194 participants in the Cancer 
Prevention Study-II (CPS-II) Nutrition Cohort, and reported protective effects of 
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being physically active both before and after cancer diagnosis. The RR of all-cause 
mortality was 0.72 (95%CI: 0.58-0.89), comparing highest to lowest category of 
prediagnostic physical activity, and 0.58 (95%CI: 0.47-0.71) when the highest 
category of postdiagnostic physical activity was compared to the lowest. In the same 
study, prediagnostic and postdiagnostic sitting time ≥6 hours/day was correlated with 
increased all-cause mortality (prediagnostic RR: 1.36, 95%CI: 1.10-1.68; 
postdiagnostic RR: 1.27, 95%CI: 0.99-1.64).  
In a comprehensive review of current evidence from prospective cohort studies 
[173], patients who participated in any amount of physical activity before and after 
diagnosis were found to be at lower risk of CRC-specific mortality compared with 
patients who did not participate in any physical activity. (prediagnostic RR: 0.75, 
95%CI: 0.65-0.87, P < 0.001; postdiagnostic RR: 0.74, 95%CI: 0.58-0.95, P = 0.02). 
 
2.5.2.4 Socio-Economic Status (SES) 
Socio-economic status, normally measured by surrogates such as income, marital 
status, and education attainment, is a major prognostic factor for CRC. A review of 42 
studies conducted throughout North America and Western Europe suggested that SES 
differences might cause considerably inequalities in access to diagnostic and 
treatment services, leading to SES variation in cancer survival [176]. Findings from 
five studies suggested that CRC patients in high social class had better survival than 
those in low social class [177-181], although the difference was only significant 
among men in Vagero‘s study [181]. Nevertheless, two other investigations showed 
non-significant socioeconomic differences in CRC survival [182, 183].  
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Chapter 3  Project 1. Dietary Patterns and Colorectal Cancer 
Recurrence and Survival 
This part of work has been published as a peer-reviewed article in BMJ Open 
[184] and can also be viewed on the journal‘s website at www.bmjopen.bmj.com. 
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3.1 Method and Materials  
3.1.1 Study Design 
This is a prospective cohort study based on data from a follow-up of 529 newly 
diagnosed CRC patients from NL, Canada. The prospective nature of design 
provides stronger observational evidence than do retrospective studies in support of 
the hypotheses. This type of study offers preliminary evidence on the roles of 
environmental determinants in cancer etiology and serves as a basis for hypotheses 
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formulation for future experimental studies, such as randomized controlled clinical 
trial [185].  
 
3.1.2 Study Population  
Patients in this prospective cohort study were enrolled through the Newfoundland 
Familial Colorectal Cancer Registry (NFCCR), described in detail elsewhere [3, 186]. 
Patients were eligible for inclusion if they were: 
                                        
1) Newly diagnosed with pathologically confirmed CRC (ICD-9 codes:   
153.0-153.9, 154.0-154.3, and 154.8 or ICD-10 codes: 18.0-18.9, 19.9, and 20.9); 
2) Diagnosed between January 1999 and December 2003; 
3) Diagnosed at the ages of 20 to 75 years;  
4) Residents of NL who had lived in NL for at least two years at the time of 
diagnosis. 
  
Eligible patients were inquired about their willingness to participate. If patients 
died before they could give consent (the median time from date of diagnosis to date of 
consent was 1.8 years), a close relative/proxy, who has lived with the patient, was 
invited to participate. Enrolling deceased cases through proxies could remove the 
potential bias of eliminating patients at a late distant stage [186]. Written, informed 
consent was required from each study participant/proxy to access their archived tumor 
tissue and medical records. As a result, the inception cohort consisted of 750 eligible 
patients (64%).  
Consenting participants completed and returned a detailed personal history 
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questionnaire (PHQ, see appendix 1), a food frequency questionnaire (FFQ, see 
appendix 2), and a family history questionnaire (FHQ). All questionnaires were 
self-completed. Assistance from study staff was available to help with understanding 
items on the questionnaires. Those who did not respond were sent a reminder card, 
and a follow-up call was made if needed. To capture additional cancer diagnosis or 
recurrence in the family after enrollment, the FHQ was distributed to participants for 
the second time midway through the follow-up.  
To be included in this analysis, patients had to have completed at least the FFQ, 
provided informative lifestyle and medical data from the PHQ, and had known vital 
status information by the end of the follow-up period (April, 2010). For patients who 
died prior to enrollment, the designated relative/proxy completed the aforementioned 
questionnaires. The final analytical cohort comprised 529 eligible participants (45%). 
The study protocol was approved by the Human Investigation Committee of 
Memorial University of Newfoundland. 
 
3.1.3 Measurement of Exposure and Relevant Variables 
3.1.3.1 Dietary Assessment and Food Grouping 
Diet was assessed using a semi-quantitative FFQ, which was developed from the 
well-known Hawaii FFQ [187] on the basis of a validated instrument adapted for the 
Canadian population
 
[188-190]; and for this study, it was modified slightly to include 
foods indigenous to the Newfoundland population (e.g., salted/pickled meat and 
smoked/pickled fish). The FFQ included 170 food items, beverages, and vitamin- and 
dietary-supplements [191]. For each food item or beverage, participants were asked to 
estimate their frequency of consumption and usual portion size as ‗Small‘, ‗Regular‘ 
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or ‗Large‘ from one year prior to cancer diagnosis. Portion sizes for specific food 
were specified and showed to participants by photographs. Nutrient and total energy 
intakes were calculated by multiplying the frequency of consumption of each food by 
the nutrient content of the portion size based on the composition values from the 2005 
Canadian Nutrient file.  
Taking a similar grouping scheme to that used elsewhere [15], we collapsed 
individual food items on the FFQ into 39 predefined food groups based on the roles of 
food in diet and cancer etiology. Distinct food items were reserved as individual 
categories if it was deemed inappropriate to combine them (e.g., jam, pies, beer, and 
wine). As a result, the 39 predefined food groups included milk, yogurt, sugar, tea, 
coffee, soft drinks, cheese, egg, mixed dishes, cured/processed red meat, 
cured/processed meat, game, poultry, fish, processed fish, fruit juice, root vegetables, 
cruciferous vegetables, other fruit, other greens, tomato sauce, other vegetables, 
beans/peas, pickled vegetables, total cereals/grains, whole grains, citrus, berries, dried 
fruit, vegetable juice, beer, white wine, red wine, liquor, desserts/sweets, pies/tarts, 
canned fruit, and jam/jelly. 
 
3.1.3.2 Covariates 
Sociodemographic data, such as age, sex, marital status, and education attainment, 
were gathered by the self-administered PHQ. The PHQ also included items regarding 
medical history, bowel screening history, physical activity, reproductive factors 
(female only), and alcohol and tobacco use. Family history of cancer was assessed by 
the FHQ. 
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3.1.3.3 Study Outcomes 
Study outcomes were ascertained from follow-up questionnaires, local 
newspapers (e.g., death notices), death certificates, autopsy, pathology, radiology, 
surgical reports, as well as physician's notes. Additional data were gathered from the 
Dr. H. Bliss Murphy Cancer Care Foundation and Statistics Canada [192]. The cause 
of death was obtained for 93 of 168 deceased patients in this cohort, classified 
according to the International Classification of Disease (ICD) codes for underlying or 
contributing cause of death [193]; the majority (91%) of these had died from CRC. 
Since specific cause of death was not available for all deceased participants, all-cause 
mortality was used for analysis. In this study, two end points were considered: the first 
was disease-free survival, defined as time from cancer diagnosis to the first confirmed 
tumor recurrence, metastasis, or death from all causes occurring up to April, 2010; the 
second end point was overall survival, measured from the date of cancer diagnosis to 
the date of death from all causes. Patients who did not have an event by the end of the 
follow-up were censored at the date of last contact.  
 
3.1.3.4 Molecular Assessment 
The p.V600E BRAF mutation and MSI status for the tumor DNA have been 
determined in previous studies using standard protocols [194, 195]. Briefly, the 
mutational hotspot c.1799T>A. (p.Val600Glu) in the BRAF gene was detected using 
BRAF V600E allele-specific primers. Positive mutations were then verified by direct 
automatic sequencing. For MSI analyses, a panel of 10 microsatellite repeats (BAT25, 
BAT26, BAT40, BAT34C4, D5S346, D17S250, ACTC, D18S55, D10S197, and 
MYCL) were used to amplify both tumor and normal DNA [194, 195]. MSI status 
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was defined as MSI-High if 30% or more of the markers were unstable and 
MS-Stable/MSI-Low if less than 30% of the markers showed instability [37, 196]. 
The primer sequences and PCR conditions are provided in detail in earlier studies 
from this cohort [186, 194, 195]. 
 
3.1.4 Statistical Analysis 
3.1.4.1 Descriptive Statistics 
Comparisons for baseline characteristics across quartiles of dietary patterns were 
performed using ANOVA test for continuous variables and Chi-Square test for 
categorical variables. Statistical significance was accepted for two-sided P<0.05. All 
data management and analyses were performed with SAS software version 9.2 (SAS 
Institute Inc, Cary, NC).  
 
3.1.4.2 Principal Component Factor Analysis 
Exploratory principal component factor analysis [197] was used to identify major 
dietary patterns based on 39 predefined food groups from the FFQ. A varimax rotation 
(orthogonal) procedure was applied to rotate these factors, meaning that it produces 
uncorrelated, easily interpreted components that explain the greatest amount of 
variance in the original food groups [198]. We determined the number of factors to 
retain for interpretation on the basis of criteria as follows: factor eigenvalue greater 
than 1.5, the scree plot, the proportion variance explained, and factor interpretability 
[23]. Patterns were labeled based on food groups with absolute rotated factor loading 
matrix greater than or equal to 0.50 on that factor. Each participant was assigned a 
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factor score for each pattern (factor) by summing the intakes from each food group 
multiplied by optimal weights (factor loadings) [17]. Individuals with a higher factor 
score had a closer adherence to that pattern [17]. 
 
3.1.4.3 Multivariate Cox Proportional Hazard Analysis 
Cox proportional hazards models, each adjusting for energy intake and critical 
covariates, were used to evaluate the association between individual dietary pattern 
and CRC recurrence and mortality, represented by hazard ratios (HR) and 95% 
confidence intervals (CI). Potential confounders were assessed by the log-rank test in 
a univariate setting; those with the p-value less than 0.1 were considered for inclusion. 
The final models only retained the items that entered the models at P<0.1 or altered 
the effect estimates by 10% or more; these include sex (male, female), age at 
diagnosis (18-49, 50-59, 60-69, and 70+ years), stage at diagnosis (I, II, III, IV), body 
mass index (BMI<25.0, 25.0-29.9, and ≥30kg/m2), marital status (single, married or 
living as married), family history (yes, no), reported screening procedure (yes, no), 
reported chemoradiotherapy (yes, no), and MSI status (MSI-high, MSS/MSI-low). All 
models were run with the adjustment for total energy intake by including total calories 
in the model. The assumption of proportional hazard rates was verified by checking 
the parallelism of the Kaplan-Meier curves and by including time-dependent 
covariates in the models to test for statistical significance [199]. 
 
3.1.4.4 Other Analyses 
Statistical linear trend was examined by modeling the median value of each 
quartile as an ordinal variable in the regression model [17]. Potential interactions were 
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evaluated by comparing estimates from stratified analyses and testing significance of 
multiplicative interaction terms with the Wald test [17]. A sensitivity analysis was 
implemented by eliminating stage-advanced patients enrolled through proxies and 
re-calculating survival time from the completion of the first questionnaire to a 
predefined event, in order to determine whether associations might vary with the 
exclusion of stage-advanced cancer. 
 
3.2 Results 
 The cohort was followed for a median of 6.4 years (minimum: 1.3 years; 
maximum: 10.9 years). A total of 168 patients died from all causes and 30 had a 
cancer recurrence or metastasis by the end of study follow-up (April, 2010). 
 
3.2.1 Dietary Patterns 
Three distinct dietary patterns, labeled ―processed meat pattern‖, ―prudent 
vegetable pattern‖ and ―high sugar pattern‖, were extracted using the aforementioned 
factor analysis procedure. These patterns explained 73.82% of total variance in the 
original 39 food groups (Table 3.4.1). A higher factor loading matrix of a given food 
group is representative of a greater contribution of that food group on that specific 
pattern. Therefore, the first pattern, termed ―processed meat‖, was characterized by 
higher loadings and thus higher consumption of cured/processed meat, 
cured/processed red meat, red meat, fish, and processed fish; the second pattern, 
labeled ―prudent vegetable‖, displayed higher loadings on other greens, other fruit, 
other vegetables, and tomato sauce; and the third pattern, named ―high sugar‖, showed 
higher loadings on desserts and sweets, pies and tarts.  
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Table 3.4.1  Factor Loadings and Explained Variances (VAR) for the Three Major Dietary Patterns 
Identified from the Food Frequency Questionnaire at baseline using a Principal Component Factor Analysis 
Food Groups Processed Meat Pattern Prudent Vegetable Pattern High Sugar Pattern 
Milk -                    0.19   - 
Yogurt -                     0.31 - 
Sugar - -0.19 0.20 
Tea - - 0.17 
Coffee 0.17                       - - 
Soft drinks 0.19                      - - 
Cheese  0.15                      0.21   - 
Egg 0.21                     - 0.16 
Mixed dishes 0.31                 0.17 0.23 
Red meat 0.69 - 0.17 
Cured/processed red meat 0.73 - 0.21 
Cured/processed meat 0.93 - - 
Game 0.23                       - - 
Poultry 0.22                       0.27 - 
Fish 0.58           0.32 -0.22 
Processed fish 0.50               0.25 - 
Fruit juice - 0.24 0.23 
Root vegetables 0.28                   - 0.15 
Cruciferous vegetables - 0.54 - 
Other fruit - 0.59   - 
Other greens - 0.60 -0.22 
Tomato sauce -                      0.50 - 
Other vegetables 0.22                    0.54 - 
Beans, peas 0.15                        0.25 - 
Pickled vegetables 0.15                      0.26 0.15 
Total cereals and grains 0.23                   0.38   0.28 
Whole grains -                    0.33 - 
Citrus - 0.34 - 
Berries - 0.45  - 
Dried fruit - 0.39 - 
Vegetable juice - 0.17 - 
Beer 0.19                    - - 
White wine - - - 
Red wine - - - 
Liquor - - - 
Desserts and sweets 0.31                        - 0.63 
Pies, tarts 0.15                       - 0.54 
Canned fruit - 0.21 0.23 
Jam, jelly -                          - 0.26 
Proportion of VAR explained (%) 39.79 22.93 11.10 
Cumulative VAR explained (%) 39.79 62.72 73.82 
Absolute loading values <0.15 were not listed for simplicity. 
Those with loadings of 0.50 or greater are in bold. 
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3.2.2 Baseline Characteristics by Quartiles of Dietary Patterns 
Higher processed meat pattern scores at baseline were detected in men, ever 
smokers, patients who were single and individuals who had higher BMI at the time of 
diagnosis (Table 3.4.2). Higher prudent vegetable pattern scores were observed in 
women, never smokers, those with a slightly later age of diagnosis and with patients 
who had a tumor harboring the p.V600E BRAF mutation. None of these characteristics 
varied significantly by quartiles of high sugar pattern scores. 
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Table 3.4.2  Baseline Characteristics of 529 Colorectal Cancer Patients by Quartiles of the Three Major Dietary Patterns a 
 Processed Meat Pattern 
P 
Valuec 
Prudent Vegetable Pattern 
P 
Valuec 
High Sugar Pattern 
P 
Valuec  Q1 
(n=132) 
Q2 
(n=132) 
Q3 
(n=133) 
Q4 
(n=132) 
Q1 
(n=132) 
Q2 
(n=132) 
Q3 
(n=133) 
Q4 
(n=132) 
Q1 
(n=132) 
Q2 
(n=132) 
Q3 
(n=133) 
Q4 
(n=132) 
Age at diagnosisb 61.4±8.7 60.6±9.0 60.2±8.8 59.3±9.3 0.29 57.4±10.3 60.1±7.9 61.0±9.0 62.1±8.0 <.0001 59.5±9.3 60.2±9.1 60.0±8.8 61.7±8.6 0.21 
Sexb                
  Female 67(50.8) 66(50.0) 39(29.3) 39(29.6)  38(28.8) 39(29.5) 58(43.6) 76(57.6)  60(45.5) 49(37.1) 51(38.3) 51(38.6)  
  Male 65(49.2) 66(50.0) 94(70.7) 93(70.5) <.0001 94(71.2) 93(70.5) 75(56.4) 56(42.4) <.0001 72(54.5) 83(62.9) 82(61.7) 81(61.4) 0.50 
Stage at diagnosis               
I/II 87(65.9) 81(61.4) 70(52.6) 71(53.8)  72(54.5) 71(53.8) 83(62.4) 83(62.9)  79(59.8) 77(58.3) 77(57.9) 76(57.6)  
III/IV 45(34.1) 51(38.6) 63(47.4) 61(46.2) 0.09 60(45.5) 61(46.2) 50(37.6) 49(37.1) 0.27 53(40.2) 55(41.7) 56(42.1) 56(42.4) 0.98 
BMI (kg/m2)                
<25.0 38(30.6) 47(36.1) 35(26.5) 27(21.1)  42(33.6) 32(24.8) 34(26.4) 38(29.7)  33(25.6) 40(31.0) 36(28.1) 38(29.7)  
  25.0-29.9 57(46.0) 52(40.0) 53(40.2) 53(41.4)  45(35.2) 57(44.2) 55(42.6) 58(45.3)  55(42.6) 47(36.4) 58(45.3) 55(43.0)  
  30 29(23.4) 31(23.9) 44(33.3) 48(37.5) 0.03 40(31.2) 40(31.0) 40(31.0) 32(25.0) 0.78 41(31.8) 42(32.6) 34(26.6) 35(27.3) 0.63 
Physical activity (MET h/wk)               
<24.9  73(55.3) 71(53.4) 56(42.1) 65(49.2)  68(51.5) 60(45.4) 69(51.9) 68(51.5)  68(51.5) 71(53.8) 69(51.9) 57(43.2)  
24.9  59(44.7) 61(46.6) 77(57.9) 67(50.8) 0.13 64(48.5) 72(54.6) 64(48.1) 64(48.5) 0.67 64(48.5) 61(46.2) 64(48.1) 75(56.8) 0.32 
Marital status                
  Single 31(23.5) 29(22.0) 18(13.5) 37(28.0)  26(19.7) 27(20.4) 27(20.3) 35(26.5)  26(19.7) 30(22.7) 30(22.6) 29(22.0)  
  Married or 
living as married 
101(76.5) 103(78.0) 115(86.5) 95(72.0) 0.04 106(80.3) 105(79.6) 106(79.7) 97(73.5) 0.50 106(80.3) 102(77.3) 103(77.4) 103(78.0) 0.93 
Smoking status                
  Ever 77(58.3) 94(71.2) 113(85.0) 104(78.8)  108(81.8) 97(73.5) 100(75.2) 83(62.9)  101(76.5) 95(72.0) 95(71.4) 97(73.5)  
  Never 55(41.7) 38(28.8) 20(15.0) 28(21.2) <.0001 24(18.2) 35(26.5) 33(24.8) 49(37.1) 0.006 31(23.5) 37(28.0) 38(28.6) 35(26.5) 0.79 
Tumor location                
  Colon 91(69.5) 90(68.2) 85(63.9) 79(59.9)  75(56.8) 91(69.5) 87(65.4) 92(69.7)  82(62.1) 85(64.9) 87(65.4) 91(68.9)  
  Rectum 40(30.5) 42(31.8) 48(36.1) 53(40.1) 0.34 57(43.2) 40(30.5) 46(34.6) 40(30.3) 0.10 50(37.9) 46(35.1) 46(34.6) 41(31.1) 0.71 
Reported chemoradiotherapy               
  Yes 36(27.3) 31(23.5) 20(15.0) 21(15.9)  24(18.2) 23(17.4) 24(18.1) 37(28.0)  30(22.7) 28(21.2) 25(18.8) 25(18.9)  
  No 96(72.7) 101(76.5) 113(85.0) 111(84.1) 0.04 108(81.8) 109(82.6) 109(81.9) 95(72.0) 0.10 102(77.3) 104(78.8) 108(81.2) 107(81.1) 0.83 
MSI status                
MSS /MSI-L 108(86.4) 110(86.6) 113(91.9) 106(86.9)  107(85.6) 104(86.7) 113(91.1) 113(88.3)  107(84.9) 106(87.6) 110(88.0) 114(91.2)  
  MSI-H 17(13.6) 17(13.4) 10(8.1) 16(13.1) 0.49 18(14.4) 16(13.3) 11(8.9) 15(11.7) 0.57 19(15.1) 15(12.4) 15(12.0) 11(8.8) 0.50 
BRAF mutation status               
Wild type 104(85.2) 107(89.9) 109(90.8) 106(93.0)  108(91.5) 103(87.3) 112(95.7) 103(84.4)  103(88.8) 110(91.7) 106(89.1) 107(89.2)  
V600E mutant 18(14.8) 12(10.1) 11(9.2) 8(7.0) 0.25 10(8.5) 15(12.7) 5(4.3) 19(15.6) 0.02 13(11.2) 10(8.3) 13(10.9) 13(10.8) 0.88 
a  Abbreviations are as follows: BMI, body mass index; CRC, colorectal cancer; MSI, microsatellite instability; MSS/MSI-L, microsatellite stable/microsatellite instability-low; MSI-H, microsatellite 
instability-high; Q1-Q4, quartile of dietary pattern scores 
b  Continuous variables presented as mean±SD (standard deviation); categorical variables presented as number 
c   P values are for the significance of the ANOVA test for continuous variables and of the Chi-Square test for categorical variables 
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3.2.3 Dietary Patterns and Cancer Recurrence or Death 
The highest quartile of processed meat pattern was significantly associated with 
poorer DFS after the adjustment for other predictors of CRC recurrence and death 
(HR: 1.82, 95%CI: 1.07-3.09), although no overall trend was observed in the HRs 
across the whole distribution of factor scores (P for trend=0.09) (Table 3.4.3). 
Nevertheless, neither the prudent vegetable pattern nor the high sugar pattern was 
observed to be significantly associated with patient outcomes (i.e., DFS and OS).  
When stratified by tumor site, however, the association between processed meat 
pattern and DFS remained statistically significant only for patients who had tumors 
located in the colon (the highest versus the lowest quartile, HR: 2.29, 95%CI: 
1.19-4.40) but not the rectum (HR: 0.97, 95%CI: 0.38-2.45). Similarly, when OS was 
the outcome, the positive association between increasing consumption of the 
processed meat pattern and mortality was restricted to patients whose tumors were 
diagnosed in the colon (the forth versus first quartiles: HR: 2.13, 95%CI: 1.03-4.43). 
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Table 3.4.3  Hazard Ratios Associated with Disease-Free and Overall Survival in Colorectal Cancer Patients for Quartiles of Dietary Patterns 
a 
 Disease-Free Survival Overall Survival 
 No. of 
Events
b
 
/No. at Risk 
Overall CRC 
HR (95%CI) 
c 
Colon cancer 
HR (95%CI) 
c 
Rectal cancer 
HR (95%CI) 
c 
No. of 
Events
b 
/No. at Risk 
Overall CRC 
HR (95%CI) 
c 
Colon cancer 
HR (95%CI) 
c 
Rectal cancer 
HR (95%CI)
 c 
Processed meat pattern  
Q1 38/132 1.00 1.00 1.00 33/132 1.00 1.00 1.00 
Q2 45/132 1.51(0.95-2.41) 1.69(0.97-2.96) 0.91(0.39-2.14) 40/132 1.47(0.89-2.44) 2.18*(1.16-4.09) 0.75(0.28-2.03) 
Q3 58/132 1.56(0.97-2.49) 1.37(0.76-2.48) 1.72(0.85-3.95) 49/133 1.32(0.78-2.22) 1.44(0.74-2.79) 1.54(0.57-4.13) 
Q4 57/132 1.82*(1.07-3.09) 2.29*(1.19-4.40) 0.97(0.38-2.45) 46/132 1.53(0.85-2.74) 2.13*(1.03-4.43) 1.17(0.41-3.36) 
P for trend 
d
   0.09 0.12 0.91  0.25 0.40 0.59 
Prudent vegetable pattern        
Q1 46/132 1.00 1.00 1.00 41/132 1.00 1.00 1.00 
Q2 54/132 1.21(0.79-1.85) 1.35(0.78-2.34) 0.97(0.47-2.01) 45/132 1.09(0.69-1.73) 1.18(0.65-2.14) 0.90(0.41-1.98) 
Q3 50/133 1.18(0.75-1.86) 1.16(0.63-2.13) 1.30(0.65-2.60) 40/133 0.82(0.49-1.36) 1.04(0.55-1.97) 0.59(0.25-1.42) 
Q4 48/131 1.12(0.69-1.84) 1.02(0.52-1.99) 1.28(0.58-2.83) 42/132 1.03(0.61-1.75) 0.96(0.47-1.96) 1.00(0.42-2.40) 
P for trend
 d
  0.62 0.83 0.19  0.90 0.60 0.92 
High sugar pattern        
Q1 42/131 1.00 1.00 1.00 30.132 1.00 1.00 1.00 
Q2 54/132 1.07(0.70-1.63) 0.96(0.54-1.68) 1.30(0.64-2.65) 48/132 1.25(0.77-2.04) 1.21(0.62-2.36) 2.12(0.87-5.14) 
Q3 54/133 1.09(0.69-1.73) 0.94(0.51-1.73) 1.44(0.67-3.07) 50/133 1.64(0.98-2.75) 1.35(0.66-2.78) 2.49*(1.02-6.10) 
Q4 48/132 1.02(0.62-1.69) 0.99(0.52-1.89) 1.49(0.61-3.63) 40/132 1.27(0.72-2.25) 1.16(0.54-2.47) 1.68(0.55-5.08) 
P for trend
 d
  0.89 0.90 0.11  0.52 0.56 0.64 
a
 Abbreviations are as follows: CRC, colorectal cancer; HR, hazard rate ratios; CI, confidence interval; Q1-Q4, quartile of dietary pattern scores. 
b
 Events are defined as death, recurrence, or metastasis (whichever occurred earliest) for disease-free survival and deaths for overall survival. 
c 
Cox proportional hazard model adjusted for total energy intake, sex, age at diagnosis, stage at diagnosis, marital status, family history, reported screening procedure, 
reported chemoradiotherapy and MSI status, where appropriate. 
d
 Two-sided P value for test of linear trend was calculated by modeling median values for each quartile of dietary pattern scores as an ordinal variable. 
* Significantly different from reference category, P<0.05. 
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In the stratified analyses for dietary patterns, there was evidence for effect 
modification by sex (P =0.04) for the association of processed meat pattern with DFS 
(HR: 3.85 for women and 1.22 for men) (Table 3.4.4). However, no evidence was 
observed to suggest that the effects of other dietary patterns on cancer recurrence or 
death were modified by physical activity, BRAF V600E mutation status and MSI (data 
not shown). 
In the sensitivity analysis, when advanced-stage patients who died before 
admittance were excluded, the association between processed meat pattern and 
survival among CRC patients remained significant. 
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Table 3.4.4  Disease-Free Colorectal Cancer Survival in Relation to Quartiles of Dietary Patterns by Selected Lifestyle and Tumor Characteristics 
a
 
 No. of Events
 
/ 
No. at Risk 
Quartiles HR (95%CI)
c
 P for 
Trend
d
 
P for 
Interaction
e
 Q1 Q2  Q3
 
 Q4
 
 
Processed meat pattern        
Sex        
Female 65/210 1.00 2.20(0.99-4.91) 2.38(0.97-5.85) 3.85*(1.49-9.99) 0.03  
  Male 133/318 1.00 1.20(0.66-2.18) 1.23(0.69-2.17) 1.22(0.64-2.32) 0.27 0.04 
Physical activity        
     <24.9 MET h/wk 97/263 1.00 1.96*(1.05-3.67) 2.13*(1.11-4.11) 2.03(0.96-4.30) 0.42  
     24.9 MET h/wk 101/264 1.00 1.22(0.59-2.55) 1.27(0.62-2.62) 1.64(0.74-3.62) 0.01 0.64 
BRAF mutation status       
     Wild type 163/425 1.00 1.28(0.77-2.12) 1.41(0.80-2.34) 1.80*(1.01-3.21) 0.009  
  V600E mutant 17/49 1.00 1.82(0.40-8.34) 0.54(0.10-2.83) 0.79(0.09-7.01) 0.50 0.80 
Prudent vegetables pattern       
Sex       
Female 65/210 1.00 1.57(0.59-4.20) 1.55(0.63-3.85) 1.22(0.46-3.24) 0.71  
  Male 133/318 1.00 1.25(0.76-2.04) 1.08(0.62-1.88) 1.14(0.62-2.09) 0.67 0.65 
Physical activity        
     <24.9 MET h/wk 97/263 1.00 1.48(0.80-2.76) 1.52(0.81-2.87) 1.22(0.56-2.69) 0.66  
     24.9 MET h/wk 101/264 1.00 1.02(0.55-1.89) 1.02(0.53-1.96) 1.05(0.55-2.04) 0.03 0.83 
BRAF mutation status       
     Wild type 163/425 1.00 1.32(0.83-2.10) 1.29(0.80-2.08) 1.19(0.70-2.02) 0.58  
     V600E mutant 17/49 1.00 2.50(0.38-16.59) 0.88(0.06-12.99) 1.24(0.12-13.20) 0.73 0.80 
High sugar pattern        
Sex        
Female 65/210 1.00 1.41(0.63-3.16) 0.88(0.36-2.15) 0.82(0.30-2.27) 0.42  
  Male 133/318 1.00 1.14(0.67-1.97) 1.34(0.75-2.39) 1.39(0.73-2.66) 0.06 0.72 
Physical activity        
     <24.9 MET h/wk 97/263 1.00 1.01(0.55-1.86) 1.10(0.56-2.16) 1.19(0.56-2.54) 0.06  
     24.9 MET h/wk 101/264 1.00 1.36(0.70-2.65) 1.21(0.60-2.45) 1.04(0.49-2.22) 0.86 0.26 
BRAF mutation status       
     Wild type 163/425 1.00 0.99(0.61-1.59) 1.20(0.71-2.01) 1.03(0.59-1.82) 0.70  
     V600E mutant 17/49 1.00 0.53(0.07-4.25) 0.27(0.04-1.66) 0.32(0.04-2.64) 0.09 0.33 
a Abbreviations are as follows: CI, confidence interval; METs/week, metabolic equivalent hours per week; Q1-Q4, quartile of dietary pattern scores 
b Events are defined as death, recurrence, or metastasis (whichever occurred earliest) for disease-free survival and deaths for overall survival. 
c Cox proportional hazard model adjusted for total energy intake, sex, age at diagnosis, stage at diagnosis, BMI, marital status, family history, reported screening procedure, reported chemoradiotherapy, and 
MSI status, where appropriate. 
d Two-sided P value for test of linear trend was calculated by modeling median values for each quartile of dietary pattern scores as an ordinal variable. 
e P for interaction is the significance of interaction term between smoking and respective stratification variable, calculated by the Wald test. 
* Significantly different from reference category, P<0.05. 
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3.3 Discussion 
Three dietary patterns, termed ―processed meat pattern‖, ―prudent vegetable 
pattern‖ and ―high sugar pattern‖, were generated in this cohort study. We found that 
high conformity with the processed meat pattern, characterized by high intakes of 
processed meat, red meat, fish, and processed fish, is associated with decreased DFS 
of CRC, specifically of colon cancer. The differential associations by subsite indicate 
disease heterogeneity. On the contrary, increasing consumption of the prudent 
vegetable pattern and the high sugar pattern displayed no clear relationships with 
mortality or recurrence.  
The processed meat pattern in the present study shares most characteristics of the 
Western diet referred to in previous studies on CRC risk, which indicates a positive 
association between the Western dietary pattern and CRC risk [21, 23]. However, 
there has been minimal research examining the association between dietary factors 
(e.g., nutrient, carbohydrate, protein and lipid intake) and survival of CRC patients 
[13, 14]; moreover, our literature review identified only one study that investigated 
the relationship between dietary patterns and survival among CRC patients. 
Consistent with our results, that prospective cohort study of 1009 stage III colon 
cancer patients [23] reported a deleterious disease-free colon cancer prognosis for 
patients reporting high levels of the Western dietary pattern intake. A prudent dietary 
pattern was not related to cancer recurrence or mortality in that study. 
 The mechanisms explaining the impact of red and processed meat on CRC 
mortality are still unclear; however, some biologic mechanisms that link diet factors 
to CRC risk may continue after diagnosis and subsequently impact cancer progression 
and survival [200]. For example, strong carcinogens such as N-nitroso compounds 
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(NOCs) and probable carcinogenic mutagens like heterocyclic amines (HCA) and 
polycylic aromatic hydrocarbons (PAH), which have been suggested as significant 
contributors for CRC development [120, 121], are found in smoked, fried or 
high-temperature cooked meat. Sandhu et al. [201] reported a Western dietary pattern 
is related to high levels of serum insulin and insulin-like growth factors (IGF), and 
these hormones are found to be associated with tumor growth and the inhibition of 
apoptosis. In addition, a growing body of evidence suggests that disruption of the 
normal gut microflora is associated with human disease, including the pathogenesis of 
the intestinal tract (e.g. inflammatory bowel disease) and other diseases such as 
obesity, cardiovascular disease, and autoimmune conditions [202, 203]. Alterations in 
intestinal microbiota are also strongly associated with colonic polyp formation and 
with the risk of developing CRC [94]. Given the major role of diet on the intestinal 
microbiome [204], our findings between dietary patterns and CRC survival may also 
be explained by the impact of dietary patterns on gut microflora and health outcomes. 
We did not observe any significant association between a prudent vegetable pattern 
and CRC survival. Given that more than 90% of adults in NL do not consume 5 
servings of fruit and vegetables per day, let alone the 7-10 servings that are 
recommended [205], it is possible that the total intake of fruits and vegetables was not 
sufficient to exert a protective effect in this cohort.  
The influence of processed meat pattern on survival was evident among women 
rather than men in our study. Previous studies revealed that the higher colon pH and 
longer intestine transit time in women compared to men can influence the production 
of secondary bile acid or NOCs [206], resulting in gender differences in the CRC 
development. This is the first study that considered effect modifications between 
dietary patterns and tumor molecular phenotype (i.e. BRAF mutation) on CRC 
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survival. BRAF V600E mutation is found to be significantly associated with poor CRC 
survival in some studies [207]; however, whether it can modify the impacts of dietary 
factors on CRC survival is not known. Although stratified analyses in our study 
demonstrated a processed meat diet to significantly decrease survival time only in 
patients with BRAF wild type tumor, no evident interactions were detected. Further 
research is clearly warranted to verify these findings and to determine the biologic 
pathways that rationalize the underlying interactions between diet and tumor 
molecular features.  
A reasonably large sample size with detailed information of patients is a merit of 
our study. These data not only include demographic and personal lifestyle information, 
but also some molecular characteristics obtained from genetic testing. The ample 
information enables us to perform stratification analysis to control and assess effect 
modifiers and confounders. Several limitations of this study should be recognized. 
Firstly, the results may be skewed by recall bias since the participants recalled their 
food consumption from one year prior to CRC diagnosis; however, this 
non-differential misclassification is only expected to bias the results towards the null. 
Secondly, dietary patterns in this study only reflect food consumption before 
diagnosis; it is unknown whether participants modified their diet post diagnosis. Since 
previous research has shown minimal change in diet between pre- and post- diagnosis 
among cancer patients [14], the current study did not examine dietary changes before 
and after diagnosis. Additionally, although we have controlled for many known 
prognostic factors, possible residual confounding might still exist. Besides, immortal 
person-time bias might impact our results; however, this is minimized by using 
proxies to enroll deceased patients. 
In summary, we found that high conformity to the processed meat pattern is 
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significantly associated with an increased risk of all-cause mortality and recurrence of 
CRC. Though our study did not find a difference in effect by tumor molecular 
phenotype, larger molecular studies should be conducted to examine if such 
differences exist. Ultimately, confirmation of these findings and the underlying 
mechanisms await further studies. Our observation not only adds to the mounting 
evidence that encourages people to engage in a healthy diet, but also provides some 
guidance to efficacious dietary interventions [22]; that is, people may lower their risk 
of CRC mortality by the avoidance of a processed meat pattern diet. 
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Chapter 4  Project 2. Influence of Prediagnostic Cigarette Smoking 
on Colorectal Cancer Survival: Overall and by Tumor Molecular 
Phenotype 
4.1 Subjects and Methods 
4.1.1 Study Participants 
A detailed description of the study cohort has been published elsewhere [186].  
In brief, participants were incident CRC patients identified through the 
population-based Newfoundland and Labrador Colorectal Cancer Registry (NFCCR). 
Eligibility criteria included patients who were: 
                                     
1) Newly diagnosed with pathologically confirmed, invasive CRC (ICD-9 codes:      
153.0-153.9, 154.0-154.3, and 154.8 or ICD-10 codes: 18.0-18.9, 19.9, and 20.9); 
2) Diagnosed between January 1999 and December 2003; 
3) Diagnosed at the ages of 20 to 75 years;  
4) Residents of NL who had lived in NL for at least two years at the time of 
diagnosis. 
 
Seven hundred and fifty consenting patients (64%) completed and returned 
detailed epidemiologic questionnaires: a Personal History Questionnaire (PHQ, see 
appendix 1), a Food Frequency Questionnaire (FFQ, see appendix 2), and a Family 
History Questionnaire (FHQ). Patients were also asked to donate a blood sample and 
for permission to access their archived tumor tissue and medical records. Exclusions 
from this analysis were made if patients had unknown clinical outcome or smoking 
status (n=41), or provided insufficient information on other critical prognostic factors 
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(n=3). Thus, the final cohort consisted of 706 eligible participants. Ethics approval for 
this study was received from the Human Investigation Committee of Memorial 
University of Newfoundland. 
 
4.1.2 Measurement of Exposure and Relevant Variables 
4.1.2.1 Assessment of Smoking Exposure and Baseline Information Collection 
The epidemiologic questionnaire included items regarding age, sex, marital status, 
education attainment, medical history, bowel screening history, medication use, 
physical activity, reproductive factors (female only), and alcohol and tobacco use.  
Participants were asked whether they have smoked at least one cigarette a day for 3 
months or longer in their life. Participants who responded ‗yes‘ were then asked about 
the age at which they started smoking, their usual number of cigarettes smoked per 
day, the duration (years/months) during which they smoked and, where applicable, the 
dates when they quit smoking. For this analysis, cigarette smoking was represented by 
categories of smoking status (never, current, or former), years of smoking (none, <20, 
20-29, and 30), cigarettes daily (none, <20 , 20-29, and 30), years of abstention 
(non-smoker, <10 , 10-29, and 30), and lifetime cigarette pack-years (none, 20, 
20-39, and 40; calculated as the average number of cigarettes smoked per day 
divided by 20 and multiplied by the number of years smoked) [133]. BMI was 
calculated as weight in kilograms divided by the square of height in meters. Clinical 
and pathologic data (e.g., tumor stage at diagnosis) were abstracted from pathology 
reports and medical records.  
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4.1.2.2 Study Outcomes 
The cohort was followed up for mortality and recurrence from diagnosis to April, 
2010. During this period, the FHQ was distributed to participants for the second time 
to collect information on additional cancer diagnosis and recurrence in their family. If 
a patient was deceased, a close proxy was asked to participate [186]. Information on 
vital status (i.e., death, recurrence, and metastasis) was gathered from follow-up 
questionnaires, local newspapers, death certificates, autopsy, pathology, radiology, 
surgical reports, as well as physician's notes. Additional data were collected from the 
Dr. H. Bliss Murphy Cancer Care Foundation [192]. For the purposes of this analysis, 
OS was the primary outcome, defined as time from CRC diagnosis to death from all 
causes. The secondary outcome, DFS, was measured from the date of cancer 
diagnosis to the date of death, recurrence, or metastasis (whichever came first). 
Patients who were still alive or who did not have a recurrence or metastasis by the end 
of the follow-up period were censored at the time of last contact. 
 
4.1.2.3 Molecular Assessment 
Molecular analyses for MSI and BRAF V600E mutation were performed using 
standard protocols as described previously [194, 195, 208]. Briefly, for MSI analyses, 
both tumor DNA and normal DNA were amplified by polymerase chain reaction 
(PCR) with a panel of 10 microsatellite markers: BAT25, BAT26, BAT34C4, BAT40, 
ACTC, D5S346, D17S250, D18S55, D10S197, and MYCL [194, 195]. The 
appearance of a discordant number of bands between tumor and normal DNA was 
interpreted as instability [194]. Tumors were classified as MSI-high if 30% or more of 
the repeats were unstable and MS-stable/MSI-Low if less than 30% of the repeats 
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demonstrated instability [37]. Exon 15 of the BRAF gene, spanning the mutational 
hotspot c.1799T>A. (p.Val600Glu), was amplified by PCR using BRAF V600E 
allele-specific primers, followed by direct automatic sequencing to verify the 
mutations [208]. Detailed descriptions of each assay, including the primer sequences 
and PCR conditions, are provided in earlier studies from this cohort [186, 194, 195, 
208]. 
 
4.1.3 Statistical Analysis 
4.1.3.1 Descriptive Statistics 
Group comparisons were performed with Dunnett‘s tests for continuous variables 
and Pearson‘s Chi-square tests of independence for categorical variables [147]. The 
Kaplan-Meier technique was applied to graphically delineate overall and stratified 
survival distributions. Statistical significance was conducted at two-sided P<0.05. All 
calculations were performed with SAS software (version 9.2). 
 
4.1.3.2 Multivariate Cox Proportional Hazard Analysis 
 Proportional hazards models were used to estimate the impact of smoking on 
mortality among CRC patients, while adjusting for co-variates. Hazard ratios (HR) 
and corresponding 95% confidence intervals (CI) were calculated for approximate 
quartiles of exposure, using never smokers as the reference group. Subjects with 
missing data on any smoking exposure variables were excluded but for specific 
smoking-related variable analysis only. In the selection approach of the multivariate 
models, we assessed an extensive list of potential confounders, including 
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demographic variables, diet, lifestyle factors, treatment, clinicopathologic, and a 
series of molecular predictors. Factors were considered for inclusion in the 
multivariable Cox model if the log-rank test had a P-value of 0.2 or less in the 
univariate setting [209]. Only terms that entered the model at P<0.1, altered the effect 
estimates by 10% or more, or improved the fit of the models were retained for the 
final models [210]. The final models in this analysis included sex (male, female), age 
at diagnosis (18-49, 50-59, 60-69, and 70+ years), BMI (<25.0, 25.0-29.9, and 
≥30kg/m2), stage at diagnosis (I, II, III, IV), marital status (single, married or living as 
married), alcohol drinking (yes, no), fruit intake (0-6, 6-7, 7-14, and >14 
servings/week), family history of CRC (yes, no), reported chemoradiotherapy (yes, 
no), and MSI status (MSI-high, MSS/MSI-low). The assumption of proportional 
hazard rates was verified by checking the parallelism of the Kaplan-Meier curves and 
by testing the statistical significance of time-dependent covariates when included in 
the model [199].  
  
4.1.3.3 Other Analyses 
Evidence of linear trends was tested by modeling ordinal variables of exposure as 
a continuous variable in the regression model [133, 211]. Potential interactions were 
evaluated by including interaction terms between smoking and respective 
stratification variable in the model with the Wald test.  
 
4.2 Results 
By the end of the follow-up period, during a maximum of 10.9 years of 
observation, there were 338 deaths from all causes.  At baseline, 506 patients were 
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ever smokers and 200 patients were never smokers. 
4.2.1 Baseline Characteristics by Smoking Status 
Current smokers were slightly younger, leaner, drank more alcohol, more likely to 
be men, and showed a greater proportion of MSI-H tumors (21.5%) compared to 
never smokers (MSI-H tumors: 10.9%, P=0.03) (Table 4.2.1). Similarly, most former 
smokers were male, married or living as married, and reported greater alcohol 
consumption and less chemoradiotherapy use relative to never smokers. 
Table 4.2.1  Selected Demographic and Clinicopathologic Characteristics of Study 
Population, by Smoking Status at Baseline 
a
 
 Never Smoker Former Smoker Current Smoker 
 No. (%) No. (%) P-value No. (%) P-value 
Age at diagnosis (years) 60.7±9.6 61.1±8.5 0.84 56.2±9.4 0.0004 
Sex      
  Women 120 (60.0) 110(29.9)  27 (36.5)  
  Men 80 (40.0) 258(70.1)  <0.0001 47 (63.5)  0.001 
BMI (kg/m
2
)      
<25.0 62 (32.6) 89 (24.8)  27 (39.1)  
  25.0-29.9 83 (43.7) 150 (41.8)  26 (37.7)  
  30 45 (23.7) 120 (33.4)  0.03 16 (23.2)   0.003 
Marital status      
  Single 57 (28.6) 63 (17.2)  27 (36.5)  
  Married or living as married 142 (71.4) 303 (82.8)  0.002 47 (63.5)  0.21 
Tumor site      
  Colon 137 (68.8) 244 (66.3)  43 (58.1)  
  Rectum 62 (31.2) 124 (33.7)  0.54 31 (41.9)  0.10 
Tumor stage at diagnosis      
I/II 100 (50.0) 186 (50.5)  46 (62.2)  
III/IV 100 (50.0) 182 (49.5) 0.90 28 (37.8)   0.07 
Alcohol drinking      
  No 130 (65.0) 96 (26.1)  14 (18.9)  
  Yes 70 (35.0) 272 (73.9) <0.0001 60 (81.1)   <0.001 
Family history of CRC      
  No 178 (89.0) 327 (88.9)  66(89.2)  
  Yes 22 (11.0) 41 (11.1) 0.96 8 (10.8) 0.96 
Reported screening procedure      
  No 176 (88.0) 316 (85.9)  69 (93.2)  
  Yes 24 (12.0) 52 (14.1) 0.48 5 (6.8) 0.21 
Reported chemoradiotherapy     
  No  142 (71.0) 306 (83.2)  60 (81.1)  
  Yes 58 (29.0) 62 (16.8)  0.001 14 (18.9)   0.09 
MSI status      
MSS /MSI-L 171 (89.1) 312 (90.2)  51 (78.5)  
  MSI-H 21 (10.9) 34 (9.8)    0.68 14 (21.5)   0.03 
BRAF mutation status      
  Wide type 164 (88.2) 289 (88.7)  58 (90.6)  
  V600E mutant 22 (11.8) 37 (11.3)   0.87 6 (9.4)     0.59 
a 
 Abbreviations are as follows: BMI, body mass index; CRC, colorectal cancer; MSI, microsatellite instability; 
MSS/MSI-L, microsatellite stable/ microsatellite instability-low; MSI-H, microsatellite instability-high.  
b   
P values are for the significance of the Dunnett‘s test for continuous variables and of the Chi-square test for 
categorical variables. 
c 
 Continuous variables presented as mean±SD (standard deviation). 
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4.2.2 Prediagnostic Smoking and Mortality 
Current smoking (HR: 1.78, 95%CI: 1.04-3.06) was significantly associated with 
higher risk of all-cause mortality in multivariable models (Table 4.2.2, Figure 4.2.1). 
The higher risks of mortality from smoking persisted in more detailed definitions of 
the exposure, including pack-years (40 pack-years, HR: 1.72, 95%CI: 1.03-2.85), 
number of cigarettes smoked daily (30 cigarettes per day, HR: 1.41, 95%CI: 
0.79-2.54), and years of smoking (30 years, HR: 1.28, 95%CI: 0.83-1.97), although, 
for the latter two variables, the risk estimates of being in the highest quartile of 
exposure did not quite attain statistical significance at the 0.05 level. Moreover, there 
was a stepwise gradient of decreasing risk of mortality with increasing years of 
abstention for former smokers (P for trend=0.03). Similarly, when DFS was the 
outcome, the HRs were elevated in the groups who had a smoking history of 30 
years (HR: 1.53, 95%CI: 1.01-2.34), individuals who smoked 30 cigarettes per day 
(HR: 1.80, 95%CI: 1.22-2.67), and those with 40 pack-years of smoking (HR: 1.99, 
95%CI: 1.25-3.19). When the data were stratified by tumor site, marked differences in 
multivariate HRs were noted (Table 4.2.2); that is, smoking was associated with 
decreased survival for colon cancer, but not for rectal cancer. Specifically, rates of 
all-cause death among colon cancer patients elevated in current smoking (HR: 2.34, 
95%CI: 1.01-5.45) and greater pack-years of smoking (40 pack-years, HR: 2.08, 
95%CI: 1.11-3.87), while incremental effects on DFS were found across categories of 
cigarette years (30 years, HR: 1.73, 95%CI: 1.03-2.93, P for trend=0.02), number of 
cigarettes smoked daily (30 cigarettes per day, HR: 2.12, 95%CI: 1.26-3.57, P for 
trend=0.15), and pack-years of smoking (40 pack-years, HR: 2.45, 95%CI: 1.34-4.46, 
P for trend=0.03).   
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Table 4.2.2  Hazard Ratios Associated with Overall and Disease-Free Survival in Colorectal Cancer Patients for Cigarette Smoking Exposures 
a
 
 Overall Survival Disease-Free Survival 
 No. of Events
b 
/No. at Risk 
c
 
Overall CRC 
HR (95%CI) 
d
 
Colon Cancer 
HR (95%CI) 
d
 
Rectal Cancer 
HR (95%CI) 
d
 
No. of Events
b  
/No. at Risk
c
 
Overall CRC 
HR (95%CI) 
d
 
Colon Cancer 
HR (95%CI) 
d
 
Rectal Cancer 
HR (95%CI)
 c
 
Cigarette status   
Non-smoker 90/200 1.00 1.00 1.00 97/200 1.00 1.00 1.00 
Ever-smoker 248/506 1.25(0.84-1.88) 1.52(0.91-2.54) 0.90(0.45-1.82) 272/505 1.30(0.90-1.88) 1.57(0.97-2.50) 0.87(0.46-1.63) 
Former 151/368 1.06(0.71-1.59) 1.46(0.87-2.45) 0.80(0.38-1.67) 172/367 1.21(0.83-1.77) 1.50(0.93-2.43) 0.82(0.43-1.57) 
Current  33/74 1.78*(1.04-3.06) 2.34*(1.01-5.45) 1.23(0.52-2.93) 36/74 1.69(0.99-2.84) 2.03(0.95-4.33) 1.11(0.48-2.55) 
Cigarette years         
<20 52/117 1.11(0.66-1.87) 1.11(0.56-2.18) 1.17(0.50-2.72) 58/117 1.26(0.77-2.03) 1.29(0.67-2.45) 1.02(0.49-2.16) 
20-29 53/107 1.13(0.67-1.89) 1.50(0.79-2.83) 0.73(0.29-1.81) 57/107 1.22(0.75-2.00) 1.61(0.87-2.99) 0.63(0.28-1.43) 
30 110/226 1.28(0.83-1.97) 1.45(0.85-2.48) 0.97(0.45-2.10) 122/225 1.53*(1.01-2.34) 1.73*(1.03-2.93) 1.01(0.52-1.99) 
P trend 
e
  0.05 0.09 0.62  0.08 0.02 0.76 
Cigarettes daily        
<20 75/186 0.95(0.60-1.52) 1.16(0.66-2.05) 0.70(0.30-1.62) 83/185 0.88(0.64-1.22) 1.03(0.70-1.52) 0.65(0.31-1.38) 
20-29 99/193 1.38(0.88-2.17) 1.47(0.82-2.63) 1.13(0.53-2.41) 105/193 1.05(0.77-1.44) 1.17(0.79-1.72) 0.85(0.43-1.70) 
30 45/77 1.41(0.79-2.54) 1.93(0.92-4.06) 0.83(0.31-2.19) 53/77 1.80*(1.22-2.67) 2.12*(1.26-3.57) 1.66(0.73-3.77) 
P trend 
e
  0.12 0.02 0.95  0.21 0.15 0.36 
Pack-years of smoking        
<20 117/257 0.96(0.61-1.50) 1.06(0.60-1.87) 0.86(0.40-1.87) 126/257 1.03(0.67-1.57) 1.20(0.70-2.08) 0.72(0.36-1.43) 
20-39  67/135 1.30(0.81-2.07) 1.43(0.79-2.57) 1.02(0.45-2.31) 73/134 1.37(0.88-2.13) 1.67(0.95-2.92) 0.87(0.41-1.83) 
40  64/114 1.72*(1.03-2.85) 2.08*(1.11-3.87) 1.07(0.43-2.66) 73/114 1.99*(1.25-3.19) 2.45*(1.34-4.46) 1.26(0.57-2.75) 
P trend 
e
  0.08 0.06 0.47  0.07 0.03 0.48 
Years of abstention 
f
        
30 28/69 1.10(0.63-1.95) 1.13(0.56-2.29) 1.08(0.41-2.87) 31/69 1.21(0.71-2.05) 1.21(0.62-2.37) 1.27(0.53-3.03) 
10-29 66/162 1.26(0.79-2.00) 1.49(0.86-2.58) 0.67(0.27-1.64) 75/162 1.36(0.88-2.10) 1.76*(1.02-3.04) 0.75(0.36-1.55) 
<10 32/77 1.28(0.74-2.20) 1.49(0.76-2.93) 0.87(0.33-2.34) 37/76 1.42(0.85-2.36) 1.77(0.92-3.41) 0.87(0.40-1.91) 
P trend 
e
  0.03 0.06 0.42  0.03 0.05 0.47 
a 
Abbreviations are as follows:
 
HR, hazard rate ratios; CI, confidence interval. 
b
 Events are defined as deaths for overall survival and death, recurrence, or metastasis (whichever occurred earliest) for disease-free survival. 
 
c
 Subjects with missing data on any smoking exposure variables are excluded but for specific smoking-related variable analysis only. 
d
Cox proportional hazard model adjusted for sex, age at diagnosis, stage at diagnosis, BMI, marital status, alcohol consumption, intake of fruits, family history, reported screening procedure, 
reported chemoradiotherapy, and MSI status, where appropriate. 
e
 Linear trend tested by modeling the ordinal variables of exposure as a continuous variable. 
f
 Excludes current smokers.  
* Significantly different from reference category, P<0.05. 
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A. 
 
B. 
 
 
Figure 4.2.1  Survival Curves for A. Overall Survival and B. Disease-Free Survival by 
Smoking Status.  Adjusted for sex, age at diagnosis, stage at diagnosis, BMI, marital status, alcohol 
consumption, family history, reported chemoradiotherapy, and MSI status. 
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4.2.3 Interactions between Smoking and Demographic or Tumor Characteristics 
The multivariable models were repeated for smoking status between strata 
defined by demographic and tumor characteristics (Table 4.2.3). The P-values for 
interaction were statistically significant between strata of sex for DFS (P=0.04) and 
age at diagnosis for OS (P=0.03). More specifically, the risk of mortality associated 
with ever smoking seemed limited to males (DFS: HR: 1.68, 95%CI: 1.16-2.44) and 
to patients aged ≥60 years at CRC diagnosis (OS: HR: 1.69, 95%CI: 1.20-2.40). In 
regard to other variables, although the interaction terms were not statistically 
significant, the impacts of smoking on mortality were more marked for patients 
diagnosed at earlier stages (OS: HR: 1.83, 95%CI: 1.07-3.14; DFS: HR: 1.70, 95%CI: 
1.04-2.78) than for those diagnosed at advanced stages (OS: HR: 1.19, 95%CI: 
0.87-1.62; DFS: HR: 1.16, 95%CI: 0.86-1.57), and for individuals with microsatellite 
stable/microsatellite instability-low (MSS/MSI-L) tumors (OS: HR: 1.38, 95%CI: 
1.04-1.82; DFS: HR: 1.32, 95%CI: 1.01-1.72) than for those with cancers exhibiting 
MSI-H (OS: HR: 1.04, 95%CI: 0.28-3.95; DFS: HR: 1.24, 95%CI: 0.37-4.14). 
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Table 4.2.3  Overall and Disease-Free Survival in Colorectal Cancer Patients in Relation to 
Cigarette Smoking by Sex, Age at Diagnosis, Stage at Diagnosis, MSI, and BRAF V600E 
Mutation Status 
a
 
 Never Smoker Ever Smoker 
b
 
P for 
Interaction 
d 
 Events 
b
/ 
At Risk 
HR 
c
 
(95%CI) 
Events 
b
/ 
At Risk 
HR 
c
 
(95%CI) 
b
 
Overall survival      
Sex      
       Men 36/80 1.00 183/350 1.65*(1.12-2.44)  
     Women 54/120 1.00 65/156 1.16(0.77-1.76) 0.12 
Age at diagnosis      
       <60 37/85 1.00 94/217 1.11(0.72-1.71)  
       60 53/115 1.00 154/289 1.69*(1.20-2.40) 0.03 
Stage at diagnosis      
I/II 21/100 1.00 79/241 1.83*(1.07-3.14)  
III/IV 69/100 1.00 169/265 1.19(0.87-1.62) 0.14 
MSI status     
MSS /MSI-L 82/171 1.00 220/420 1.38*(1.04-1.82)  
       MSI-H 5/21 1.00 11/51 1.04(0.28-3.95) 0.24 
BRAF mutation status     
       Wide type 72/164 1.00 197/397 1.15(0.75-1.77)  
       V600E mutant 13/22 1.00 27/54 1.65(0.42-6.53) 0.42 
Disease-free survival      
Sex      
       Men 38/80 1.00 202/350 1.68*(1.16-2.44)  
     Women 59/120 1.00 70/155 1.01(0.69-1.48) 0.04 
Age at diagnosis      
       <60 41/85 1.00 108/217 1.11(0.74-1.66)  
       60 56/115 1.00 164/288 1.61*(1.15-2.26) 0.08 
Stage at diagnosis      
I/II 25/100 1.00 92/240 1.70*(1.04-2.78)  
III/IV 72/100 1.00 180/265 1.16(0.86-1.57) 0.10 
MSI status      
MSS /MSI-L 89/171 1.00 239/419 1.32*(1.01-1.72)  
       MSI-H 5/21 1.00 16/51 1.24(0.37-4.14) 0.82 
BRAF mutation status     
       Wide type 78/164 1.00 216/396 1.23(0.83-1.82)  
       V600E mutant 14/22 1.00 30/54 1.45(0.44-4.82) 0.52 
a 
Abbreviations are as follows: HR, hazard rate ratios; CI, confidence interval. 
b
 Events are defined as deaths for overall survival and death, recurrence, or metastasis (whichever 
occurred earliest) for disease-free survival; ever smokers are former and current smokers combined. 
c 
Cox proportional hazard model adjusted for sex, age at diagnosis, stage at diagnosis, BMI, marital 
status, alcohol consumption, and MSI status, where appropriate. 
d
 P for interaction is the significance of interaction term between smoking and respective stratification 
variable, calculated by the Wald test. 
* Significantly different from reference category, P<0.05. 
 
4.3 Discussion 
We examined smoking status and gradients of smoking duration/intensity in 
relation to OS and DFS in a cohort of CRC patients. Pre-diagnostic smoking was 
associated with higher risk of mortality and poorer DFS. Evidence suggests that the 
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association between smoking and decreased survival was restricted to patients whose 
tumors were diagnosed in the colon only. Our work replicates the findings from a 
recent analysis in Washington State [37], in which, CRC patients who currently smoke 
have significantly higher disease-specific (HR: 1.30; 95%CI: 1.09-1.74) and all-cause 
mortality (HR: 1.51; 95%CI: 1.24-1.83) than non-smokers. These authors also 
reported higher associations of smoking on mortality for patients diagnosed with 
colon cancer than for rectal cancer. Likewise, another study in Tayside city [38], UK, 
with a cohort of CRC patients receiving curative surgery, found significantly worse 
cause-specific survival in active smokers compared with non-smokers (HR: 2.55; 
95%CI: 1.40-4.64). Notably, current smoking, but not former smoking, was associated 
with worsened survival. This is important since it suggests that CRC patients who still 
smoke at the time of diagnosis could improve their survival by smoking cessation 
[38].   
There are several biologic mechanisms that may explain the higher mortality 
among CRC patients who smoke. First, tobacco smoking may mutate the GSTM1 
gene, resulting in impaired detoxification of tobacco carcinogens [147]; these 
carcinogens may exert growth promoting effects to residual tumor cells, either 
through resistance to chemotherapy or through promotion of angiogenesis [38, 212]. 
Smoking may also induce aberrant promoter DNA methylation, thus silencing 
regulatory genes (e.g., ECAD, p16, MGMT, and DAPK) in tumor progression [148].  
Possible explanations for the differential associations by subsite include the higher 
concentration of tobacco carcinogens in the colon and the longer contact time of 
tobacco constituent-carrying feces with the colon, where they are mainly stored, than 
the rectum [213]. 
In this study, cigarette smoking was associated with decreased survival only 
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among male patients. Plausible mechanisms that rationalize the sex differences in 
survival reduction attributable to tobacco exposure might include the protective 
effects of female sex hormones on cancer prognosis [214] and the reduced androgen 
concentration caused by smoking [215, 216] that may lead to stimulation of bowel 
carcinomas among men [217, 218]. 
Our findings suggest that smoking has a negligible impact on survival for those 
diagnosed with advanced-stage disease, perhaps because patient outcomes are 
inherently poor for this patient population irrespective of smoking status. Intriguingly 
however, smoking was observed to be significantly associated with poorer survival in 
patients diagnosed with early-stage disease, providing further support for the 
recommendation that newly diagnosed patients with less advanced CRC should 
consider immediate smoking cessation [219]. 
Smoking is strongly associated with specific somatic molecular alterations (e.g. 
microsatellite-instability phenotype, CpG island methylator phenotype (CIMP) and 
the p.V600E BRAF mutation [220]) that are linked with the MSI and serrated 
pathways of carcinogenesis [45]. As these alterations are also strongly related to 
overall survival, it is important to evaluate the influence of smoking on survival 
stratified by molecular features of the patients‘ tumors (e.g., MSI and BRAF mutation 
status).  Our study is among the first to assess possible interactions between MSI, 
BRAF V600E, and smoking on both OS and DFS for CRC. We found that ever 
smoking was associated with higher risk of mortality among patients diagnosed with 
MSS/MSI-L tumors whereas smoking had little impact on patients diagnosed with 
MSI-H tumors (Table 4.2.3). To our knowledge, only one previous study on smoking 
and CRC survival has considered potential effect modification by molecular 
phenotypes of tumor (i.e., MSI status) [37]. Phipps et al. [37] reported a prominent 
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association between smoking and disease-specific mortality in CRC patients with 
MSI-H tumors (HR: 3.83; 95%CI: 1.32-11.11). Our data suggest that cigarette 
smoking per se does not universally confer poor survival to CRC patients, but rather 
that its effect diverges according to genetic background or, possibly, the oncogenic 
pathways of tumorigenesis [46]. More research is clearly needed to verify these 
findings and to understand the mechanisms that link smoking to decreased survival 
among colorectal cancer patients.  
This study has both strengths and limitations. Firstly, the reasonably large sample 
size allowed us to perform stratified analyses. The availability of detailed information 
on personal, clinicopathologic, and molecular characteristics also allowed us to assess 
potential confounders, effect modifiers, and sources of potential heterogeneity.  
Moreover, a significant portion of patients in this study were chronic smokers; thus 
these data have the unique advantage of examining an association that is thought to 
have a long latent period [221, 222]. Limitations to this study include a lack of 
information on the cause of death for all deceased participants. The observed 
differences in OS and DFS could be deaths from causes other than CRC. However, 
the cause of death, classified according to the ICD codes, was obtained for 200 of 338 
deceased patients in this cohort. Of these, the majority (86%) had died from CRC, 
which is in line with other studies [223, 224]. Secondly, smoking is self-reported by 
respondents from the distant past, and cigarette-use after diagnosis was not updated. 
Self-reported cigarette consumption has been shown to be accurate in current smokers 
but is misreported in approximately 20% of never smokers [147, 225]; however, such 
misclassification should be non-differential and therefore bias the study results toward 
the null [147].  
In conclusion, pre-diagnosis cigarette smoking is independently predictive of 
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worse survival after CRC diagnosis. Results from this prospective population-based 
study underscore the importance of cultivating healthy lifestyle habits. This study 
presents preliminary results concerning potential interactions between smoking, 
clinicopathologic, and tumor molecular phenotype on CRC survival. Confirmation of 
these findings is needed in large replication studies and further analyses using 
tobacco-specific DNA adducts as quantitative measurements of exposure are 
warranted [147].  
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Chapter 5  Summary 
The research project presented in this thesis comprises two components. The first 
mainly investigated the associations of dietary patterns and CRC all-cause (OS) and 
disease-free survival (DFS), and further explored if the relationship between dietary 
pattern and CRC survival was modified by sex, physical activity and BRAF mutation. 
Results showed that high conformity to the processed meat pattern was significantly 
associated with an increased risk of all-cause mortality and recurrence of CRC, 
whereas no associations were observed with the prudent vegetable or the high sugar 
patterns and DFS. The effect of processed meat pattern on cancer recurrence or death 
was modified by sex. This observation not only adds to the mounting evidence that 
encourages people to engage in a healthy diet, but also provides some guidance to 
efficacious dietary interventions; that is, people may lower their risk of CRC mortality 
by the avoidance of a processed meat pattern diet. 
Nevertheless, this study is limited in self-reported dietary exposures from the past 
and dietary changes before and after diagnosis that have not been accounted for in the 
analyses. The choice of foods in the questionnaire is another source of bias. Some 
food items that are not listed on the questionnaire (e.g., some ‗snacks‘) may comprise 
a large part of a typical diet and are also laden in sugars, salt and fat. Lack of such 
information may bias the dietary pattern analyses. Therefore, the initial findings 
need to be confirmed in a replicated. Further research should be more concerned with 
the development of more robust and discriminating dietary assessment methodologies 
for identifying dietary patterns that are valid and reproducible. Though our study did 
not find a difference in effect by tumor molecular phenotype (i.e., MSI status or BRAF 
V600E mutation), larger molecular studies should be conducted to examine if such 
differences exist.  
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The second component of this thesis examined the association of smoking with 
OS and DFS among CRC patients; and further assessed potential interactions of 
smoking with sex, age at diagnosis, tumor stage at diagnosis, MSI status, and BRAF 
mutation status on cancer mortality. Results obtained from this part of study 
demonstrated that pre-diagnosis cigarette smoking is independently predictive of 
worse survival after CRC diagnosis, and the relationship between smoking and CRC 
survival is modified by sex and age at diagnosis. Our results underscore the 
importance of cultivating healthy lifestyle habits. This study presents preliminary 
results concerning potential interactions between smoking, clinicopathologic, and 
tumor molecular phenotype on CRC survival.  
Limitations to this study include a lack of information on the cause of death for all 
deceased participants. The observed differences in OS and DFS could be deaths from 
causes other than CRC. Secondly, smoking is self-reported by respondents from the 
distant past, and cigarette-use after diagnosis was not updated. Hence, confirmation of 
these findings is needed in large replication studies. Further directions would involve 
the use of tobacco-specific DNA adducts, which allows more precisely quantitative 
identification of smoking exposure values.  
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Appendices 
Appendix 1. Personal History Questionnaire 
 
Please write in your answers where space is provided, or place tick marks in circles О 
 
What date are you filling out this questionnaire?   _____/_____/_____ 
                                                                                
Day   Month Year  
 
Identifying information 
 
1. Are you male or female?  О male 
 О female 
  
2. What is your date of birth? ___ ___ years 
 О don‘t know 
  
2. What is your age? day ___ ___ 
 month   ___ ___ 
 year ___ ___ 
 О don‘t know day 
 О don‘t know month 
 О don‘t know year 
  
3. Are you a twin or triplet? ┌  О yes, a twin 
 ├  О yes, other multiple (triplet, quadruplet, etc.): ___________ 
 
│                                                                             
Please specify 
 │ О no 
 │ О don‘t know 
 │ 
 └  If yes, please read the following statement and answer the  
 question. 
  
 Non-identical twins are no more alike than ordinary brothers 
 and sisters. Genetically identical twins, on the other hand,  
 look so much alike *that is, they have a strong resemblance  
 to each other in height, colouring, features of the face, etc.)  
 that people often mistake one for the other, especially during  
 their childhood. 
  
 Do you have a genetically identical twin or triplet? 
 О yes 
 О no 
 О don‘t know 
  
5. What is your marital status? О currently married or living as married 
 О separated 
 О divorced 
 О widowed 
 О single or never married 
 О don‘t know 
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Bowel Screening and Health 
  
  
6. Have you ever had a test for blood in your  7. Have you ever had a sigmoidoscopy?  
stool, called a smear test or a hemoccult?  sigmoidoscopy involves looking inside the  
This test is frequently done as part of a  lower bowel and rectum with a lighted  
routine physical examination, or it can be  instrument. This examination is usually  
done at home. done in a doctor‘s office without anesthesia. 
  
О yes О yes 
О no → Please go to # 7 О no → Please go to # 8 
О don‘t know → Please go to # 7 О don‘t know → Please go to # 8 
  
6a. When did you first have this test? 7a. When did you first have this test? 
  
age when first tested ___ ___ age when first tested ___ ___ 
or or 
year of first test ___ ___ ___ ___ year of first test ___ ___ ___ ___ 
О don‘t know О don‘t know 
  
6b. What were the reasons for your first test? 7b. What were the reasons for your first  
Please tick all that apply. sigmoidoscopy? Please tick all that apply. 
  
О to investigate a new problem О to investigate a new problem 
О family history of colorectal cancer О family history of colorectal cancer 
О routine/yearly examination or check-up О routine/yearly examination or check-up 
О follow up of previous problem О follow up of previous problem 
О don‘t know О don‘t know 
  
6c. How many times have you had a hemoccult  7c. How many times have you had a  
test? sigmoidoscopy? 
  
___ number of hemoccult tests ___ number of sigmoidoscopies 
О don‘t know О don‘t know 
  
6d. If you have had a hemoccult test more than  7d. If you have had a sigmoidoscopy more than  
once, when did you last have this test? once, when did you last have this test? 
  
age when last tested ___ ___ age when last tested ___ ___ 
or  or  
year of last test ___ ___ ___ ___ year of last test ___ ___ ___ ___ 
О don‘t know О don‘t know 
8.  Have you ever had a colonoscopy? 9.  Has a doctor ever told you that you had  
colonoscopy is an examination of the entire  polyps in your large bowel or colon or  
large bowel using a long flexible  rectum? Polyps are growths in the lining of  
instrument. This examination is usually  the colon which vary in size from a tiny dot  
done under sedation. several inches. 
  
О yes О yes 
О no → Please go to # 9 О no → Please go to # 10 
О don‘t know → Please go to # 9 О don‘t know → Please go to # 10 
  
8a. When did you first have this test? 9a. When did your doctor first tell you that you  
 have had polyps? 
age when first tested ___ ___  
or age when first tested ___ ___ 
year of first test ___ ___ ___ ___ or 
О don‘t know year of first test ___ ___ ___ ___ 
 О don‘t know 
8b. What were the reasons for your first   
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colonoscopy? Please tick all that apply. 9b. Have you been told more than once that 
 you had polyps? 
О to investigate a new problem  
О family history of colorectal cancer О yes 
О routine/yearly examination or check-up О no 
О follow up of previous problem О don‘t know 
О other: __________________________  
              Please specify 9c. When did you your doctor last tell you that 
О don‘t know you had polyps? 
  
8c. How many times have you had a age at last diagnosis ___ ___  
colonoscopy? or 
 year of last diagnosis ___ ___ ___ ___ 
___ number of colonoscopies О don‘t know 
О don‘t know  
  
8d. If you have had a colonoscopy more than  9d. Do you know what kind of polyps they  
once, when did you last have this test? were? 
  
age when last tested ___ ___ О benign 
or  О adenomatous (pre-cancerous) 
year of last test ___ ___ ___ ___ О hyperplastic 
О don‘t know О other: __________________________ 
               Please specify 
 О don‘t know 
 
 
9e.  Did you have the polyps removed (by a 11.  Has a doctor ever told you that you had  
procedure called a polypectomy)? (This can  Crohn‘s disease? This is where you have an  
be done during a sigmoidoscopy or   inflammation that extends into the deeper 
colonoscopy.)  layers of the intestinal wall. It may also  
 affect other parts of the digestive tract, 
О yes including the mouth, esophagus, stomach, 
О no → Please go to # 10 and small intestine. 
О don‘t know → Please go to # 10  
 О yes 
9f. When did you first have polyps removed? О no → Please go to # 12 
 О don‘t know → Please go to # 12 
age at first polypectomy ___ ___  
or 11a. When did your doctor first tell you that  
year of first polypectomy ___ ___ ___ ___ you had Crohn‘s disease? 
О don‘t know  
 age when first tested ___ ___ 
9g. Have you had polyps removed more than  or 
once?  year of first test ___ ___ ___ ___ 
 О don‘t know 
О yes  
О no 12.  Has a doctor ever told you that you had  
О don‘t know ulcerative colitis? This is an inflammation  
 and ulceration of the lining of the bowel  
9h. If you have had polyps removed more than  (colon) & rectum. It is not a stomach ulcer. 
once, when did you last have polyps   
removed? О yes 
 О no → Please go to # 13 
age at first polypectomy ___ ___ О don‘t know → Please go to # 13 
or  
year of first polypectomy ___ ___ ___ ___ 12a. When did your doctor first tell you that  
О don‘t know you had ulcerative colitis? 
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10. Has a doctor ever told you that you had  age at first diagnosis ___ ___ 
familial adenmotaous polyposis, known or 
also as FAP? This is a condition,  year of diagnosis ___ ___ ___ ___ 
sometimes occurring in families, in which  О don‘t know 
numerous polyps line the inside of the large   
bowel or colon. 13. Has a doctor ever told you that you had  
 irritable bowel syndrome? This is a  
О yes disorder of the bowels leading to cramping,  
О no → Please go to # 11 gassiness, bloating and alternating diarrhea  
О don‘t know → Please go to # 11 and constipation. It is sometimes called  
 IBS, or spastic colon.  
10a. When did your doctor first tell you that   
you had FAP? О yes 
age at first diagnosis ___ ___ О no → Please go to # 14 
or О don‘t know → Please go to # 14 
year of diagnosis ___ ___ ___ ___  
О don‘t know  
 
 
13a. When did your doctor first tell you that  15b.  Have you had more than one surgery to   
you had irritable bowel syndrome? remove your bowel or colon?  
  
age at first diagnosis ___ ___ О yes 
or О no → Please go to # 16 
year of diagnosis ___ ___ ___ ___ О don‘t know → Please go to # 16 
О don‘t know  
 15c. When did you last have any of your  
14.  Has a doctor ever told you that you had  bowel or colon removed? 
diverticular disease? This may also be   
called diverticulosis or diverticulitis.  age at last operation ___ ___ 
It‘s a condition in which the bowel may   or 
become infected, and can lead to pain and  year of last operation ___ ___ ___ ___ 
chronic problems with bowel habits. О don‘t know 
and small intestine.  
 16. Have you had your gallbladder removed? 
О yes  
О no → Please go to # 15 О yes 
О don‘t know → Please go to # 15 О no → Please go to # 17 
 О don‘t know → Please go to # 17 
14a. When did your doctor first tell you that   
you had diverticular disease? 16a. When did you have your gallbladder   
 removed? 
age at first diagnosis ___ ___  
or age at operation ___ ___ 
year of diagnosis ___ ___ ___ ___ or 
О don‘t know year of operation ___ ___ ___ ___ 
 О don‘t know 
15. Have you ever had any of your large bowel  
or colon removed? 17. Has a doctor ever told you that you had  
 diabetes, also known as diabetes mellitus? 
О yes Please do not include diabetes which you  
О no → Please go to # 16 had only during pregnancy. 
О don‘t know → Please go to # 16  
 О yes 
Was it completed removed, or was only part  О no → Please go to # 14 
of it removed? О don‘t know → Please go to # 14 
О completed removed  
О partly removed  
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О don‘t know   
  
15a. When did you first have any of your  17a. When did your doctor first tell you that  
bowel or colon removed? you had diabetes? 
  
age at first operation ___ ___ age at first diagnosis ___ ___ 
Or or 
year of first operation ___ ___ ___ ___ year of diagnosis ___ ___ ___ ___ 
О don‘t know О don‘t know 
 
 
 
17b. Did you ever take medication to control   18.  Has a doctor ever told you that you had  
your diabetes? high cholesterol? If your doctor told you it   
 borderline, please tick no. 
О yes  
О no → Please go to # 18 О yes 
О don‘t know → Please go to # 18 О no → Please go to # 19 
 О don‘t know → Please go to # 19 
17c. What type of medication did you use, pill  
or insulin injections? 18a. When did your doctor tell you that you 
 had high cholesterol? 
О pills  
О insulin injections age at diagnosis ___ ___ 
О both or 
О don‘t know → Please go to # 18 year of diagnosis ___ ___ ___ ___ 
 О don‘t know 
17d. How often did you usually take it?  
Please choose the most appropriate  18b. How you ever take medication to control  
category. your high cholesterol? 
  
 Pills Insulin О yes 
times per day or ___ ___ ___ ___ О no → Please go to # 19 
times per week or ___ ___ ___ ___ О don‘t know → Please go to # 19 
times per month or ___ ___ ___ ___  
times per year ___ ___ ___ ___ 18c. How often did you usually take it? Please 
don‘t know О О choose the most appropriate category. 
  
17e. About one year before your recent cancer  ___ ___ times per day or 
diagnosis, were you taking it? ___ ___ times per week or 
 ___ ___ times per month or 
 Pills Insulin ___ ___ times per year or 
О yes О О О don‘t know 
О no  О О  
О don‘t know  О О 18d. About one year before your recent cancer 
 diagnosis, were you taking it? 
17f. How long, in total, have you taken this   
medication? О yes 
 О no  
 Pills Insulin О don‘t know 
number of moths or ___ ___ ___ ___  
number of years ___ ___ ___ ___ 18e. How long, in total, have you taken this 
don‘t know О О medication? 
  
 ___ ___ number of months or 
 ___ ___ number of years 
 О don‘t know 
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19. Has a doctor ever told you that you had  20.  Has a doctor ever told you that you had  
high levels of fat (other than cholesterol) in any type of cancer?  
your blood, also called high triglycerides?  
If your doctor told you it was borderline,  О yes 
Please tick no. О no → Please go to # 24 
 О don‘t know → Please go to # 24 
О yes  
О no → Please go to # 20 20a. What type of cancer was it? 
О don‘t know → Please go to # 20 _____________________ cancer 
  
19a. What did your doctor first tell you that  20b. When did your doctor tell you that you 
you had high triglycerides? had this type of cancer? 
  
age at diagnosis age at diagnosis ___ ___ 
or  or 
year of diagnosis year of diagnosis ___ ___ ___ ___ 
don‘t know О don‘t know 
  
19b. Did you ever take medication to control  20c. Were you treated with radiation therapy  
the high levels of fat in your blood? (radiotherapy) for this cancer? 
  
О yes О yes 
О no → Please go to # 20 О no  
О don‘t know → Please go to # 20 О don‘t know  
  
19c. How often did you usually take it?  21.  Has a doctor ever told you that you had  
Please choose the most appropriate  any other cancer? 
category.  
 О yes 
___ ___ times per day or О no → Please go to # 24 
___ ___ times per week or О don‘t know → Please go to # 24 
___ ___ times per month or  
___ ___ times per year or 21a. What type of cancer was it? 
О don‘t know _____________________ cancer 
  
19d. About one year before your recent cancer  21b. When did your doctor tell you that you 
diagnosis, were you taking it? had this type of cancer? 
  
О yes age at diagnosis ___ ___ 
О no  or 
О don‘t know year of diagnosis ___ ___ ___ ___ 
 О don‘t know 
  
19e. How long, in total, have you taken this 21c. Were you treated with radiation therapy  
medication? (radiotherapy) for this cancer? 
  
___ ___ number of months or О yes 
___ ___ number of years О no  
О don‘t know О don‘t know  
 
 
 
 
19. Has a doctor ever told you that you had  Medications  
any cancer?  
 Have you ever taken any of the following  
О yes medications regular (at least twice a week  
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О no → Please go to # 24 for more than a month)? 
О don‘t know → Please go to # 24  
  
22a. What type of cancer was it?  
  
_________________cancer  
  
22b. When did your doctor first tell you that  24. Aspirin (such as Anacin, Bufferin, Bayer,  
you had this type of cancer? Excedrin, Ecotrin) 
  
age at diagnosis О yes 
or  О no → Please go to # 25 
year of diagnosis О don‘t know → Please go to # 25 
don‘t know  
  
22c. Were you treated with radiation therapy    
(radiotherapy) for this cancer?  
  
О yes 24a. How often did you usually take it when  
О no  you were taking it regularly (that is, at least  
О don‘t know  twice a week for more than a month)?  __ 
 Please choose one of the following.  
23. Has a doctor ever told you that you had    
any other cancer?  ___ ___ times per day or  
 ___ ___ times per week 
О yes О don‘t know 
О no → Please go to # 24  
О don‘t know → Please go to # 24  
  
22a. What type of cancer was it?  
 24b. About one year before your recent cancer 
_________________cancer diagnosis, were you taking it regularly? 
  
23b. When did your doctor first tell you that  О yes 
you had this type of cancer? О no  
 О don‘t know  
age at diagnosis  
or   
year of diagnosis 24c. How long, in total, have you taken this  
don‘t know medication regularly? If you started and 
 stopped and then started again, please _ 
23c. Were you treated with radiation therapy   count only the time you were taking this  
(radiotherapy) for this cancer? medication. 
  
О yes ___ ___ number of months or  
О no  ___ ___ number of years 
О don‘t know  О don‘t know 
 
 
 
 
Have you ever taken any of the following medications regularly  
(at least twice a week for more than a month)? (continued) 
  
  
  
  
25. Acetaminophen (such as Tylenod,  26. Ibuprofen medications (such as Advil,  
Anacin-3, Panadol) Motrin, Medipren, Indocid, Naprosyn,  
 NSAIDS (NSAIDS are non-steroidal anti- 
 inflammatory drugs) 
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О yes О yes 
О no → Please go to # 26 О no → Please go to # 27 
О don‘t know → Please go to # 26 О don‘t know → Please go to # 27 
  
  
  
25a. How often did you usually take it when  26a. How often did you usually take it when  
you were taking it regularly (that is, at least  you were taking it regularly (that is, at least  
twice a week for more than a month? twice a week for more than a month? 
Please choose one of the following.  Please choose one of the following.  
  
___ ___ times per day or  ___ ___ times per day or  
___ ___ times per week ___ ___ times per week 
О don‘t know О don‘t know 
  
  
  
25b. About one year before your recent cancer 26b. About one year before your recent cancer 
diagnosis, were you taking it regularly? diagnosis, were you taking it regularly? 
  
О yes О yes 
О no  О no  
О don‘t know  О don‘t know  
  
  
  
25c. How long, in total, have you taken this  26c. How long, in total, have you taken this  
medication regularly? If you started and medication regularly? If you started and 
stopped and then started again, please _ stopped and then started again, please _ 
count only the time you were taking this  count only the time you were taking this  
medication. medication. 
  
___ ___ number of months or  ___ ___ number of months or  
___ ___ number of years ___ ___ number of years 
О don‘t know О don‘t know 
 
 
 
 
Have you ever taken any of the following medications regularly  
(at least twice a week for more than a month)? (continued) 
  
  
  
  
27. Bulk-forming laxatives (such as  28. Other laxatives (such as Ex-Lax,  
Metamucil, Citrucel, FibreCon.  Correctol, Dulcolax, Senokot, Colace,  
Serutan, psyllium) castor, cod liver oil, mineral oil,  
 milk of magnesia, lactulose, Epsom salts) 
  
О yes О yes 
О no → Please go to # 28 О no → Please go to # 29 
О don‘t know → Please go to # 28 О don‘t know → Please go to # 29 
  
  
  
27a. How often did you usually take it when  28a. How often did you usually take it when  
you were taking it regularly (that is, at least  you were taking it regularly (that is, at least  
twice a week for more than a month? twice a week for more than a month? 
Please choose one of the following.  Please choose one of the following.  
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___ ___ times per day or  ___ ___ times per day or  
___ ___ times per week ___ ___ times per week 
О don‘t know О don‘t know 
  
  
  
27b. About one year before your recent cancer 28b. About one year before your recent cancer 
diagnosis, were you taking it regularly? diagnosis, were you taking it regularly? 
  
О yes О yes 
О no  О no  
О don‘t know  О don‘t know  
  
  
  
27c. How long, in total, have you taken this  28c. How long, in total, have you taken this  
medication regularly? If you started and medication regularly? If you started and 
stopped and then started again, please _ stopped and then started again, please _ 
count only the time you were taking this  count only the time you were taking this  
medication. medication. 
  
___ ___ number of months or  ___ ___ number of months or  
___ ___ number of years ___ ___ number of years 
О don‘t know О don‘t know 
 
 
 
 
Have you ever taken any of the following medications regularly  
(at least twice a week for more than a month)? (continued) 
  
  
  
29. Multivitamin supplements (such as  30. Folic acid or folate pills or tablets  
One-A-Day, Theragram, Centrum,   
Unicap) (not individual vitamins)  
  
  
О yes О yes 
О no → Please go to # 28 О no → Please go to # 31 
О don‘t know → Please go to # 28 О don‘t know → Please go to # 31 
  
  
  
29a. How often did you usually take it when  30a. How often did you usually take it when  
you were taking it regularly (that is, at least  you were taking it regularly (that is, at least  
twice a week for more than a month? twice a week for more than a month? 
Please choose one of the following.  Please choose one of the following.  
  
___ ___ times per day or  ___ ___ times per day or  
___ ___ times per week ___ ___ times per week 
О don‘t know О don‘t know 
  
  
  
29b. About one year before your recent cancer 30b. About one year before your recent cancer 
diagnosis, were you taking it regularly? diagnosis, were you taking it regularly? 
  
О yes О yes 
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О no  О no  
О don‘t know  О don‘t know  
  
  
  
29c. How long, in total, have you taken this  30c. How long, in total, have you taken this  
medication regularly? If you started and medication regularly? If you started and 
stopped and then started again, please _ stopped and then started again, please _ 
count only the time you were taking this  count only the time you were taking this  
medication. medication. 
  
___ ___ number of months or  ___ ___ number of months or  
___ ___ number of years ___ ___ number of years 
О don‘t know О don‘t know 
 
 
 
Have you ever taken any of the following medications regularly  
(at least twice a week for more than a month)? (continued) 
  
  
31. Calcium pills or tablets  32. Calcium-based antacids (such as   
 Tums, Rolaids, Extra-strength Rolaids, 
 Alka-Mints, Chooz Antacid gum) 
  
О yes О yes 
О no → Please go to # 32 О no →  If female, 
О don‘t know → Please go to # 32  Please go to # 33 
  If male. 
  Please go to # 44 
 О don‘t know →  If female, 
  Please go to # 33 
  If male. 
  Please go to # 44 
   
29a. How often did you usually take it when  32a. How often did you usually take it when  
you were taking it regularly (that is, at least  you were taking it regularly (that is, at least  
twice a week for more than a month? twice a week for more than a month? 
Please choose one of the following.  Please choose one of the following.  
  
___ ___ times per day or  ___ ___ times per day or  
___ ___ times per week ___ ___ times per week 
О don‘t know О don‘t know 
  
29b. About one year before your recent cancer 32b. About one year before your recent cancer 
diagnosis, were you taking it regularly? diagnosis, were you taking it regularly? 
  
О yes О yes 
О no  О no  
О don‘t know  О don‘t know  
  
29c. How long, in total, have you taken this  32c. How long, in total, have you taken this  
medication regularly? If you started and medication regularly? If you started and 
stopped and then started again, please _ stopped and then started again, please _ 
count only the time you were taking this  count only the time you were taking this  
medication. medication. 
  
___ ___ number of months or  ___ ___ number of months or  
___ ___ number of years ___ ___ number of years 
О don‘t know О don‘t know 
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 Men: please go to #44 on page 17 
 Women: please continue with #33 on page 13 
 
 
 
Menstruation, Pregnancy, and Menopause  
 
33. How old were you when you had your first  34c. How many of your pregnancies resulted in  
menstrual period? live births? 
  
___ ___ years of age О never 
О don‘t know  ___ ___ number of pregnancies with 
О never had a menstrual period live-born children 
 О don‘t know 
  
34. Have you ever been pregnant? 34d. How old were you at the first live birth?  
  
┌  О yes age at first birth ___ ___ or 
│  О no → Please go to # 35 year of first birth ___ ___ ___ ___ 
│  О don‘t know → Please go to # 35 О don‘t know 
└>How many times have you been   
pregnant? Please include miscarriages, 34e. How old were you at the last live birth?  
stillbirths, tubal pregnancies and   
abortions. age at last birth ___ ___ or 
 year of last birth ___ ___ ___ ___ 
___ ___ number of pregnancies О don‘t know 
О don‘t know   
  
34a. How many times were you pregnant with  35. Have you ever used birth control pills or  
more than one baby (twins, triplets or ___  other hormonal contraceptives (implants or  
more)? If you are pregnant now, please do  injections) for at least one year? 
not include your current pregnancy. _  
 ┌  О yes 
О never │  О no → Please go to # 36 
___ ___ number of pregnancies │  О don‘t know → Please go to # 36 
with more than one baby └>How old were you when you first used 
О don‘t know Any of these hormonal contraceptives? 
  
 age at first use ___ ___ or 
 year of first use ___ ___ ___ ___ 
 О don‘t know 
  
34b. How many of your pregnancies lasted 6   
months or longer? (Pregnancy usually lasts  
9 months. Six months is about the earliest a    
baby could survive.) If you are pregnant   
now, please do not include your current _ 35a. Were you still using hormonal  
pregnancy. contraceptives about one year before your  
 recent cancer diagnosis? 
О never  
___ ___ number of pregnancies lasting О yes 
6 months or longer О no  
О don‘t know О don‘t know  
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35b. In total, how long did you take these  Please complete the next few questions which  
hormonal contraceptives? If you started and  ask about surgeries you may have had. 
stopped and then started again, please count   
only the time you were taking these  39. Hysterectomy (only the uterus or womb 
contraceptives. Removed) 
  
___ ___ number of years ┌  О yes 
О don‘t know │  О no 
 │  О don‘t know 
36. Have you had a menstrual period in the last  └>age when removed ___ ___ or 
12 months? Please include only menstrual  years when removed ___ ___ ___ ___ 
bleeding, not bleeding that results from  О don‘t know 
hormonal replacement therapy (HRT) or   
progesterones, progesttins or withdrawal  39a. Hysterectomy with one ovary or part of an  
bleeding. Ovary removed) 
  
О yes → Please go to #42 ┌  О yes 
О no │  О no 
О don‘t know → Please go to #42 │  О don‘t know 
 └>age when removed ___ ___ or 
Have your periods stopped permanently years when removed ___ ___ ___ ___ 
or only temporarily due to pregnancy,  О don‘t know 
breast-feeding, or other conditions?  
  
О permanently  
О temporarily → Please go to #42  
  
37. How old were you when your periods  39b. Hysterectomy with both ovaries removed  
stopped permanently?  
 ┌  О yes 
age they stopped ___ ___ or │  О no 
year they stopped ___ ___ ___ ___ │  О don‘t know 
О don‘t know └>age when removed ___ ___ or 
 years when removed ___ ___ ___ ___ 
 О don‘t know 
  
38. Why did your menstrual periods stop  39c. One ovary removed, completely or partly,  
permanently? Please tick all that apply. without hysterectomy 
  
О natural menopause ┌  О yes 
О surgery  │  О no 
О radiation or chemotherapy │  О don‘t know 
О other reason └>age when removed ___ ___ or 
Please specify: ____________________ years when removed ___ ___ ___ ___ 
О Don‘t know О don‘t know 
 
 
 
39d. Both ovaries removed without  42a. Were you still having menstrual  
hysterectomy periods when you first took these  
 hormones? 
┌  О yes  
│  О no О yes 
│  О don‘t know О no 
└>age when removed ___ ___ or О don‘t know 
years when removed ___ ___ ___ ___  
О don‘t know  
  
40. If you had radiation or chemotherapy, when  42b. Were you prescribed either an estrogen- 
did you first have it? only pill or patch (such as Premarin) for  
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 hormone replacement therapy? 
┌  О had radiation or chemotherapy  
└>age when this was given ___ ___ or ┌  О yes 
year when this was given ___ ___ ___ _ │  О no 
О don‘t know │  О don‘t know 
О never had radiation or chemotherapy  └>How old were you when you first  
 took estrogen-only medication? 
41. if your periods stopped permanently for   
any reason other than surgery, radiation or  age when first taken ___ ___ or 
chemotherapy, when did you this occur? years when first taken ______ ___ _ 
 О don‘t know 
┌  О other reason  
│      Please specify: 
__________________ 
 
└>age when occurred ___ ___ or  
year when occurred ___ ___ ___ ___  
О don‘t know   
О not applicable  
  
42. Doctors prescribe hormonal replacement  42c. Were you still using estrogen-only 
therapy for many reasons, including medication for hormone replacement  
menopausal symptoms, surgical removal of  therapy about one year before your recent 
the ovaries, osteoporosis, and heart disease cancer diagnosis? 
prevention. (Menopausal symptoms include   
hot flashes, sweating, and depression.) О yes 
 О no 
Have you ever taken hormonal replacement  О don‘t know 
therapy prescribed by a doctor and in the   
form of a pill or a patch?  
  
Please do not include hormonal therapy that 42d. In total, how long did you take estrogen- 
was prescribed for birth control, infertility,  only medication for hormone replacement 
hormone therapy delivered by injections,  therapy? If you started and stopped and  
vagina creams or vaginal suppositories, or  then started again, please count only  
herbal or soy products. the time you were taking this medication. 
  
О yes ___ ___ number of months or  
О no → Please go to #43 ___ ___ number of years 
О don‘t know → Please go to #43 О don‘t know 
 
 
 
 
42e.  Progesterone or progestin is frequently 43. Have you ever taken tamoxifen, raloxifene,  
prescribed by doctors together with  or other anti-estrogen medication (such as 
estrogen for hormone replacement therapy.  Lupron or Depo-Provera)? 
One common brand name is Provera.   
Another one is Prometrium. Have you ever  ┌  О yes 
taken progesterone or progestin together  │  О no → Please go to #44 
with estrogens for hormone replacement  ├  О possibly – I have participated in a  
therapy? │      clinical trial for tamoxifen or  
 │      other anti-estrogen medication 
┌  О yes │   
│  О no → Please go to #43 │  О don‘t know 
│  О don‘t know → Please go to #43 │   
└>How old were you when you first took  └>What anti-estrogen medication did you  
progesterone or progestin  take? Please tick all that apply. 
together with estrogens?  
 О tamoxifen 
age when first taken ___ ___ or О raloxifene 
year when first taken ___ ___ ___ ___  О other: _________________________ 
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О don‘t know Please specify 
  
42f. Were you still using progesterone or  43a. How old were you when you first took 
progestin medication about one year before tamoxifen, raloxifene or other anti- 
your recent cancer diagnosis? estrogen medication? 
  
О yes age when first taken ___ ___ or 
О no year when first taken ___ ___ ___ ___  
О don‘t know О don‘t know 
  
 43b. Were you still using tamoxifen,  
 raloxifene or other anti- estrogen  
 medication about one year before your 
 recent cancer diagnosis? 
  
 О yes 
 О no 
 О don‘t know 
  
42g. In total, how long did you take  43c. In total, how long did you take tamoxifen, 
progesterone or progestin together with  raloxifene or other anti-estrogen  
estrogens? If you started and stopped  and medication? If you started and stopped and  
then started again, please count only the  then started again, please count only the  
time you were taking this medication. time you were taking this medication. 
  
___ ___ number of months or ___ ___ number of months or 
___ ___ number of years ___ ___ number of years 
О don‘t know О don‘t know 
 
 
 
Diet 
 
44. About one year before your recent cancer diagnosis, on average, how often did you eat a piece  
serving of fruit? 
(A serving of fruit is: 1 medium-sized fresh fruit; ½ cup of chopped, cooked or canned fruit; 
¼ cup of dried fruit; 6 ounces of fruit juice (50%-100% pure juice).) Please choose one of the  
following. 
 
___ ___ servings per day or  
___ ___ servings per week or 
___ ___ servings per month 
О don‘t know 
 
 
45. About one year before your recent cancer diagnosis, on average, how often did you eat a piece  
serving of vegetables? 
(A serving of vegetables is: 1 medium-sized fresh vegetables; ½ cup of chopped, cooked or  
chopped vegetables; 6 ounces of vegetable juice (50%-100% pure juice).) Please choose one  
of the following. 
 
___ ___ servings per day or  
___ ___ servings per week or 
___ ___ servings per month 
О don‘t know 
 
46. About one year before your recent cancer diagnosis, on average, how often did you eat a  
serving of red meat (not chicken or fish)? 
 
(A serving of red meat is: 2-3 ounces of red meat (a piece of meat about the size of a deck 
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of cards). Red meats include: beef, steak, hamburger, prime rib, ribs, beef hot dogs, beef- 
based processed meat, veal, pork, bacon, pork sausage, ham, lamb, venison.) 
 
___ ___ servings per day or  
___ ___ servings per week or 
___ ___ servings per month 
О don‘t eat red meat  → Please go to #47 
О don‘t know 
 
46a. About one year before your recent cancer diagnosis, on average, how often did you eat a  
serving of red meat that was cooked by broiling, grilling, barbecueing or pan-frying (not 
stir-fried or deep-fried)? Please choose one of the following. 
 
___ ___ servings per day or  
___ ___ servings per week or 
___ ___ servings per month 
О don‘t eat red meat that was cooked by these methods → Please go to #47 
О don‘t know 
 
 
46b. On average, when you ate red meat cooked by these methods, which of the following best  
describes its appearance? 
 
What was its outside appearance? What was its inside appearance? 
 (how well done it was)? 
  
О lightly browned О red (rare) 
О medium browned О pink (medium) 
О heavily browned or blackened О brown (well-done) 
О don‘t know О don‘t know 
 
 
47. About one year before your recent cancer diagnosis, on average, how often did you  eat a 
serving of chicken? Please do not include turkey or any other bird. 
(A serving of chicken is: 2-3 ounces of chicken meat; 1 drumstick; 1 thigh; half a breast;  
2 wings; 3 nuggets.) Please choose one of the following. 
 
___ ___ servings per day or  
___ ___ servings per week or 
___ ___ servings per month 
О don‘t eat red meat that was cooked by these methods → Please go to #48 
О don‘t know 
 
 
47a. About one year before your recent cancer diagnosis, on average, how often did you eat a  
serving of chicken that was cooked by broiling, grilling, barbecueing or pan-frying (not 
stir-fried or deep-fried)? Please choose one of the following. 
 
___ ___ servings per day or  
___ ___ servings per week or 
___ ___ servings per month 
О don‘t eat chicken that was cooked by these methods → Please go to #48 
О don‘t know 
 
 
47b. On average, when you ate chicken cooked by these methods, which of the following best  
describes its appearance? 
 
What was its outside appearance? 
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О lightly browned 
О medium browned 
О heavily browned or blackened 
О don‘t know 
 
 
 
We would like you to think back to when you were in your 20s and remember the physical  
activities you participated in then. 
 
48. In your 20s, did you participate regularly in physical activity for a total of at least 30 minutes  
a week? Please describe your activities below.  
 
  For how During those  During those months, 
  many years? years, for many on average, for how  
   months per year? many minutes or 
    hours per week? 
     
Walking О yes → ___ ___ years ___ ___ months __ minutes per week / 
 О no    __hours per week 
     
Jogging О yes → ___ ___ years ___ ___ months __ minutes per week / 
(running slower О no    __hours per week 
than a mile in      
10 minutes)     
     
Running О yes → ___ ___ years ___ ___ months __ minutes per week / 
(running faster  О no    __hours per week 
than a mile in     
10 minutes)     
     
Bicycling О yes → ___ ___ years ___ ___ months __ minutes per week / 
(including  О no    __hours per week 
using an      
exercise bicycle     
     
Swimming laps О yes → ___ ___ years ___ ___ months __ minutes per week / 
 О no    __hours per week 
     
Tennis, squash О yes → ___ ___ years ___ ___ months __ minutes per week / 
racquetball О no    __hours per week 
     
Calisthenics, О yes → ___ ___ years ___ ___ months __ minutes per week / 
aerobics, О no    __hours per week 
vigorous dance     
(including      
ballet), using a     
rowing machine,     
lifting weights     
     
Football, soccer О yes → ___ ___ years ___ ___ months __ minutes per week / 
rugby,  О no    __hours per week 
basketball     
     
Heavy household О yes → ___ ___ years ___ ___ months __ minutes per week / 
work (examples: О no    __hours per week 
using a non-     
power mower,     
shoveling,      
moving heavy      
loads, scrubbing     
floors)     
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In your 20s, did you do any other strenuous activities? Strenuous activity means something that  
really increased your heart rate, make you hot, and caused you to sweat. Some examples are:  
skiing, skating, hockey, hunting, shedding or tobogganing, water-skiing. 
 
Activity   For how During those  During those months, 
Please specify  many years? years, for many on average, for how  
   months per year? many minutes or 
    hours per week? 
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
  ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
     
     
49. When you were in your 20s, what was your usual occupation? (When mean what you did for  
the longest time, including any paid or unpaid employment, such as being a student or  
housewife of being unemployed.) 
 
______________________________________________________________ occupation 
О don‘t know 
 
If you are younger than 31, please go to the next section (Alcohol Consumption) on page 25. 
Otherwise, please continue with #50. 
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Now, please think back to your 30s and 40s.  
 
50. In your 30 and 40s, did you participate regularly in physical activity for a total of at least 30  
minutes  a week? Please describe your activities below.  
 
  For how During those  During those months, 
  many years? years, for many on average, for how  
   months per year? many minutes or 
    hours per week? 
     
Walking О yes → ___ ___ years ___ ___ months __ minutes per week / 
 О no    __hours per week 
     
Jogging О yes → ___ ___ years ___ ___ months __ minutes per week / 
(running slower О no    __hours per week 
than a mile in      
10 minutes)     
     
Running О yes → ___ ___ years ___ ___ months __ minutes per week / 
(running faster  О no    __hours per week 
than a mile in     
10 minutes)     
     
Bicycling О yes → ___ ___ years ___ ___ months __ minutes per week / 
(including  О no    __hours per week 
using an      
exercise bicycle     
     
Swimming laps О yes → ___ ___ years ___ ___ months __ minutes per week / 
 О no    __hours per week 
     
Tennis, squash О yes → ___ ___ years ___ ___ months __ minutes per week / 
racquetball О no    __hours per week 
     
Calisthenics, О yes → ___ ___ years ___ ___ months __ minutes per week / 
aerobics, О no    __hours per week 
vigorous dance     
(including      
ballet), using a     
rowing machine,     
lifting weights     
     
Football, soccer О yes → ___ ___ years ___ ___ months __ minutes per week / 
rugby,  О no    __hours per week 
basketball     
     
Heavy household О yes → ___ ___ years ___ ___ months __ minutes per week / 
work (examples: О no    __hours per week 
using a non-     
power mower,     
shoveling,      
moving heavy      
loads, scrubbing     
floors)     
 
 
 
 
In your 30s and 40s, did you do any other strenuous activities? Strenuous activity means  
something that really increased your heart rate, make you hot, and caused you to sweat. Some  
examples are: skiing, skating, hockey, hunting, shedding or tobogganing, water-skiing. 
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Activity   For how During those  During those months, 
Please specify  many years? years, for many on average, for how  
   months per year? many minutes or 
    hours per week? 
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
  ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
     
     
51. When you were in your 30s and 40s, what was your usual occupation? (When mean what you  
did for the longest time, including any paid or unpaid employment, such as being a student or  
housewife of being unemployed.) 
 
______________________________________________________________ occupation 
О don‘t know 
 
If you are younger than 31, please go to the next section (Alcohol Consumption) on page 25. 
Otherwise, please continue with #50. 
 
 
Now, please think back to since you turned 50s.  
 
52. In your 50s, did you participate regularly in physical activity for a total of at least 30  
minutes  a week? Please describe your activities below.  
 
  For how During those  During those months, 
  many years? years, for many on average, for how  
   months per year? many minutes or 
    hours per week? 
     
Walking О yes → ___ ___ years ___ ___ months __ minutes per week / 
 О no →   __hours per week 
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Jogging О yes → ___ ___ years ___ ___ months __ minutes per week / 
(running slower О no →   __hours per week 
than a mile in      
10 minutes)     
     
Running О yes → ___ ___ years ___ ___ months __ minutes per week / 
(running faster  О no →   __hours per week 
than a mile in     
10 minutes)     
     
Bicycling О yes → ___ ___ years ___ ___ months __ minutes per week / 
(including  О no →   __hours per week 
using an      
exercise bicycle     
     
Swimming laps О yes → ___ ___ years ___ ___ months __ minutes per week / 
 О no →   __hours per week 
     
Tennis, squash О yes → ___ ___ years ___ ___ months __ minutes per week / 
racquetball О no →   __hours per week 
     
Calisthenics, О yes → ___ ___ years ___ ___ months __ minutes per week / 
aerobics, О no →   __hours per week 
vigorous dance     
(including      
ballet), using a     
rowing machine,     
lifting weights     
     
Football, soccer О yes → ___ ___ years ___ ___ months __ minutes per week / 
rugby,  О no →   __hours per week 
basketball     
     
Heavy household О yes → ___ ___ years ___ ___ months __ minutes per week / 
work (examples: О no →   __hours per week 
using a non-     
power mower,     
shoveling,      
moving heavy      
loads, scrubbing     
floors)     
 
 
 
 
In your 50s, did you do any other strenuous activities? Strenuous activity means  
something that really increased your heart rate, make you hot, and caused you to sweat. Some  
examples are: skiing, skating, hockey, hunting, shedding or tobogganing, water-skiing. 
 
Activity   For how During those  During those months, 
Please specify  many years? years, for many on average, for how  
   months per year? many minutes or 
    hours per week? 
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
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____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
____________ → ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
  ___ ___ years ___ ___ months __ minutes per week / 
    __hours per week 
     
     
     
     
53. When you were in your 50s, what was your usual occupation? (When mean what you  
did for the longest time, including any paid or unpaid employment, such as being a student or  
housewife of being unemployed.) 
 
______________________________________________________________ occupation 
О don‘t know 
 
 
 
 
 
 We would like you to think back to when you were in your 20s. 
54. In your 20s, did you ever consume any alcoholic beverages at least once a week for 6  
months or longer? Please describe your consumption below. 
 
  For how many  During those years,  
  years? how much did you 
   typically consume? 
    
Beer, hard cider  О yes → ___ ___ years consumed ___ ___ number of 12 ounce 
(at least 3%  О no   cans or bottles 
alcohol) О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Wine   О yes → ___ ___ years consumed ___ ___ number of 4 ounce 
 О no   glasses of wine 
 О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Sake, sherry, port О yes → ___ ___ years consumed ___ ___ number of 1 ounce 
 О no   servings 
 О don‘t know  О per day 
   О per week 
   О don‘t know 
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Spirits, liquor О yes → ___ ___ years consumed ___ ___ number of 1 ounce  
mixed drinks,  О no   shots liquor or  
brandy, liqueurs О don‘t know  spirits 
   О per day 
   О per week 
   О don‘t know 
 
55. When you were in your 20s, how many years in total did you consume at least one alcoholic  
beverage (of any type) a week? 
 
___ ___ years consumed 
О never consumed alcohol 
 
56. On average, how many alcoholic beverages a week did you consume during those years? 
That is, how many 4 ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 
1 ounce servings of sake, sherry, port, or spirits, mixed drinks and cocktails. 
 
___ ___ years consumed 
О never consumed alcohol 
 
If you are younger than age 31, please go to the next section (Smoking) on page 28. 
Otherwise, please continue with #57.  
 
 
 
Now, please think back to your 30s and 40s. 
57. In your 30s and 40s, did you ever consume any alcoholic beverages at least once a week for 6  
months or longer? Please describe your consumption below. 
 
  For how many  During those years,  
  years? how much did you 
   typically consume? 
    
Beer, hard cider  О yes → ___ ___ years consumed ___ ___ number of 12 ounce 
(at least 3%  О no   cans or bottles 
alcohol) О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Wine   О yes → ___ ___ years consumed ___ ___ number of 4 ounce 
 О no   glasses of wine 
 О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Sake, sherry, port О yes → ___ ___ years consumed ___ ___ number of 1 ounce 
 О no   servings 
 О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Spirits, liquor О yes → ___ ___ years consumed ___ ___ number of 1 ounce  
mixed drinks,  О no   shots liquor or  
brandy, liqueurs О don‘t know  spirits 
   О per day 
   О per week 
   О don‘t know 
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58. When you were in your 30s and 40s, how many years in total did you consume at least one  
alcoholic beverage (of any type) a week? 
 
___ ___ years consumed 
О never consumed alcohol 
 
56. On average, how many alcoholic beverages a week did you consume during those years? 
That is, how many 4 ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 
1 ounce servings of sake, sherry, port, or spirits, mixed drinks and cocktails. 
 
___ ___ years consumed 
О never consumed alcohol 
 
If you are younger than age 51, please go to the next section (Smoking) on page 28. 
Otherwise, please continue with #60.  
 
 
 
 
 
Now, please think back to since you turned 50s. 
60. In your 50s, did you ever consume any alcoholic beverages at least once a week for 6  
months or longer? Please describe your consumption below. 
 
  For how many  During those years,  
  years? how much did you 
   typically consume? 
    
Beer, hard cider  О yes → ___ ___ years consumed ___ ___ number of 12 ounce 
(at least 3%  О no   cans or bottles 
alcohol) О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Wine   О yes → ___ ___ years consumed ___ ___ number of 4 ounce 
 О no   glasses of wine 
 О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Sake, sherry, port О yes → ___ ___ years consumed ___ ___ number of 1 ounce 
 О no   servings 
 О don‘t know  О per day 
   О per week 
   О don‘t know 
    
Spirits, liquor О yes → ___ ___ years consumed ___ ___ number of 1 ounce  
mixed drinks,  О no   shots liquor or  
brandy, liqueurs О don‘t know  spirits 
   О per day 
   О per week 
   О don‘t know 
 
61. When you were in your 30s and 40s, how many years in total did you consume at least one  
alcoholic beverage (of any type) a week? 
 
___ ___ years consumed 
О never consumed alcohol 
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62. On average, how many alcoholic beverages a week did you consume during those years? 
That is, how many 4 ounce glasses of wine or 12 ounce cans or bottles of beer or hard cider, or 
1 ounce servings of sake, sherry, port, or spirits, mixed drinks and cocktails. 
 
___ ___ years consumed 
О never consumed alcohol 
 
 
 
 
Smoking 64. Have you ever smoked at least one  
 cigar a month for at least 3 months? 
63. Have you ever smoked at least one   
cigarette a day for 3 months or longer? О yes 
 О no → Please go to #65 
О yes О don‘t know → Please go to #65 
О no → Please go to #64  
О don‘t know → Please go to #64 64a. When did you first start smoking at  
 least one cigar a month? 
63a. When did you first start smoking at   
least one cigarette a day? age at first use ___ ___ or 
 year of first use ___ ___ ___ ___ 
age at first use ___ ___ or О don‘t know 
year of first use ___ ___ ___ ___  
О don‘t know 64b. During periods when you smoked  
 regularly, how many cigar did you 
63b. During periods when you smoked  typically smoke in a month? 
regularly, how many cigarettes did you  
typically smoke in a day? ___ ___ ___ ___ cigarettes per month 
 О don‘t know 
___ ___ ___ ___ cigarettes per day  
О don‘t know 64c. About one year before your recent  
 cancer diagnosis, were you still  
63c. About one year before your recent  smoking at least one cigar a month? 
cancer diagnosis, were you still smoking   
at least one cigarette a day? О yes 
 О no  
О yes О don‘t know  
О no   
О don‘t know  64d. Do you still smoke at least one  
 cigar a month? 
63d. Do you still smoke at least one   
cigarette a day? О yes 
 О no → Please go to #64f 
О yes О don‘t know → Please go to #64f 
О no → Please go to #63f  
О don‘t know → Please go to #63f 64e. When did you stop smoking at least 
 one cigar a month (we mean stop  
63e. When did you stop smoking at least smoking permanently)? 
one cigarette a day (we mean stop   
smoking permanently)? age at first use ___ ___ or 
 year of first use ___ ___ ___ ___ 
age at first use ___ ___ or О don‘t know 
year of first use ___ ___ ___ ___  
О don‘t know 64f. How many years, in total, did you  
 smoke at least one cigar a month for 3 
63f. How many years, in total, did you  months or longer? (If you have stopped  
smoke at least one cigarette a day for 3 and restarted at least once, count only  
months or longer? (If you have stopped  the time when you were smoking.) 
and restarted at least once, count only   
the time when you were smoking.) ___ ___ ___ ___ total number of years 
 О don‘t know 
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___ ___ ___ ___ total number of years  
О don‘t know  
 
 
 
 
65. Have you ever smoked at least one  Height and Weight 
pipe a month for at least 3 months?  
 66. About how tall are you, without your  
О yes shoes on? 
О no → Please go to #66  
О don‘t know → Please go to #66 ___ feet ___ ___ inches 
 or 
65a. When did you first start smoking at  ___ ___ ___ centimeters 
least one pipe a month? О don‘t know 
  
age at first use ___ ___ or 67. How much did you weigh about one  
year of first use ___ ___ ___ ___ year before your recent cancer diagnosis? 
О don‘t know  
  ___ pounds 
65b. During periods when you smoked  Or 
regularly, how many pipe did you ___ ___ ___ kilograms 
typically smoke in a month? О don‘t know 
  
___ ___ ___ ___ pipe per month  
О don‘t know  
  
65c. About one year before your recent  Additional Information 
cancer diagnosis, were you still smoking   
at least one pipe a month? 69. Previous to this study, have you and  
 your relatives ever taken part in any  
О yes family health studies? 
О no   
О don‘t know  О yes 
 О no  
65d. Do you still smoke at least one  О don‘t know  
pipe a month?  
  
О yes  
О no → Please go to #65f  
О don‘t know → Please go to #65f  
  
65e. When did you stop smoking at least  
one pipe a month (we mean stop smoking  
smoking permanently)?  
  
age at first use ___ ___ or  
year of first use ___ ___ ___ ___  
О don‘t know  
  
65f. How many years, in total, did you   
smoke at least one pipe a month for 3  
months or longer? (If you have stopped   
and restarted at least once, count only the   
time when you were smoking.)  
  
___ ___ ___ ___ total number of years  
О don‘t know  
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Background Information 
 
70. What is the highest level of education that you completed? 
  
О less than 8 years О some college or university 
О 8 to 11 years О bachelor‘s degree 
О high school graduate О graduate degree 
О vocational or technical school О don‘t know 
 
71. Country of birth sometimes affects disease risk. Please fill in country of birth for  
yourself, you parents and your grandparents. 
 
In addition, scientists have found that some genetic traits are more common or less  
common among Jewish people of different ethnic backgrounds. Please answer the  
questions about Jewish descent for each person. 
 
 Country Is this  Ashkenazi Sephardic Other  Don‘t 
 of birth person of (East   know 
  Jewish European)    
  descent?     
       
You  ______ О yes О  О  О  О  
  О no     
  О don‘t know     
       
Your   ______ О yes О  О  О  О  
mother  О no     
  О don‘t know     
       
Your  ______ О yes О  О  О  О  
father  О no     
  О don‘t know     
       
Your  ______ О yes О  О  О  О  
mother‘s  О no     
mother  О don‘t know     
       
Your  ______ О yes О  О  О  О  
mother‘s   О no     
father  О don‘t know     
       
Your  ______ О yes О  О  О  О  
father‘s  О no     
mother  О don‘t know     
       
Your  ______ О yes О  О  О  О  
father‘s  О no     
father  О don‘t know     
 
 
 
 
 
72. How many years have you lived in Canada? 
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О all my life 
___ ___ number of years 
О don‘t know 
 
73. Ethnicity and race sometimes affect disease risk. Scientists have found that some  
genetic traits are more common or less common among people of different backgrounds.  
We would like to know if this is true for genes associated with colorectal cancer. 
 
Please fill in the background for yourself, your parents and your grandparents. 
Please tick all that apply. 
 
 You  Your  Your  Your Your Your Your  
  mother father Mother‘s Mother‘s Father‘s  Father‘s 
    mother father mother Father 
        
Black, О О О О О О О 
From Africa        
Black, from О О О О О О О 
Caribbean         
(Trinidad,         
Jamaica,         
Haiti)        
Black from О О О О О О О 
North America        
Black, other О О О О О О О 
White О О О О О О О 
First Nations О О О О О О О 
(Indian, Inuit)        
North African О О О О О О О 
(Egyptian)        
Middle East О О О О О О О 
(Iranian)        
Filipino О О О О О О О 
Japanese О О О О О О О 
Korean О О О О О О О 
Chinese О О О О О О О 
Other South  О О О О О О О 
East Asian        
(Vietnamese)        
South Asian О О О О О О О 
(East Indian,        
Pakistani)        
Other:          
Please specify ______  ______  ______  ______  ______  ______  ______  
Don‘t know О О О О О О О 
 
 
 
 
 
 
74. Which of the following categories best describes your total annual household income 
about one year before your recent diagnosis? 
 
О no income О $40,000 - $49,999 
О less than $6,000 О $50,000 - $59,999 
О $6,000 - $11,999 О $60,000 - $69,999 
О $12,000 - $19,999 О $70,000 - $79,999 
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О $20,000 - $29,999 О $80,000 +  
О $30,000 - $39,999 О don‘t know 
  
 
75. In case we need to contact you in the future and you have moved, could we have the 
name of someone who is not living with you to whom we might write or call for your  
new address? 
 
Name of relative or friend: __________________________________________________ 
His or her address:  ________________________________________________________ 
________________________________________________________________________ 
His or her telephone number: (___ ___ ___) ___ ___ ___ - ___ ___ ___ ___  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you very much for taking the time to fill out this questionnaire. 
We appreciate your participation. 
 
Please mail this completed questionnaire in the return envelope provided.  
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Appendix 2. Food Frequency Questionnaire 
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